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The science of genotoxicity mainly concerns with the fact that 
chemicals, which induce mutations in various experimental models. 
may conceivably affect the incidence of heritable mutations in man. 
Chemicals can be tested for their ability to induce chromosomal 
damage either in microbes, plants, animals, insects, mammals, and 
cultured mammalian cells. Mammalian cell cultures provide a 
convenient test system and either established cell lines or human 
blood lymphoc>1:es can be used in practice. Genotoxicity tests can be 
defmed as in vitro or m vivo tests designed to detect drugs. \N hich can 
induce genetic damage directly or indirectly by various mechanism of 
action. These tests enable hazard identification with respect to DNA 
damage and its fixation in the form of genetic muatations. large-scale 
chromosomal damage, recombination and numerical chrotnosome 
changes. Various chemicals and drugs are tested positive for 
genotoxicity applying these tests. 
('ardiovascular diseases (CVD) are considered as one of the 
most dreaded challenges the world faces today. These diseases 
account for nearly a third of all deaths worldwide. These are 
increasing in developing countries at an alarming rate and it has been 
estimated that CVD will be the major cause of morbidity and 
mortality in these countries by the year 2020. The main factor leading 
to this widespread and chronic problem is hypertension. Hypertension, 
being chronic, requires long-term drug therapy and thus interaction of 
antihypertensive drugs and their metabolites is direct and continual 
1^ 
with the human body. The duration of pharmacological treatment ot 
hypertension may last for decades and, therefore, patients are exposed 
to prolonged contact with the drugs. Long-term treatments require 
documentation of long-term safety and efficacy trials including 
sensitive indices of genotoxic damage. 
Antihypertensive vasodilators are drugs that are recommended 
for the treatment of peripheral vascular diseases, high biood pressure 
problems, cardiac problems like stroke and other cerebral vascular 
diseases etc, depending on the function and class of that particular 
antih\pertensive drug. Prolonged drug therapy emploxing such drugs 
ma\ produce adverse side-effects, and may even affect the heritable 
material. 
Several studies had earlier been done to evaluate the 
genotoxicity of commonly recommended cardiovascular drugs and 
reported in literature. Hydrochlorothiazide, used as a diuretic and 
antihypertensive agent, was studied to produce micronuclei (VIN) in 
cultured human lymphocytes. A data from 164 marketed 
antihypertensive drugs showed that out of therri, 32 drugs were tested 
positive in at least one genotoxicit}^ assay, 26 in at least one 
carcinogenicity assay, and 10 in at least both, one genotoxicity assa} 
and one carcinogenicity assay. Antihypertensive drug nimodipine was 
studied to induce micronuclei in vitro. Nitrovasodilators. used in 
nitrate therapy were observed to cause possible genotoxic acti\it\. 
Likewise some other widely used antihypertensive vasodilators, like. 
Atenolol, Hydralazine and Dihydralazine, Methyldopa were also 
reported to induce some genotoxic effects in cultured human 
lymphocytes in vitro as well as in vivo in patients. 
The cardiac problems are, nowadays, common!} encountered 
and the treatment is prescribed for decades via drug therap\. Thus, in 
the present investigation, keeping in mind the widespread, long-term 
and constant use of vasodilator antihypertensives, four such drugs are 
tested for their cytogenetic effects in vitro in human peripheral blood 
lymphocytes. These drugs are Pentoxifylline (Trental"). Isoxsuprine 
hydrochloride (Duvadilan'), Xanthinol nicotinate (Complamina") and 
Metoprolol tartrate (Metolar*). No such type of study has been done 
previously in three of these drugs, namely, Duvadilan \ C omplamina' 
and Metolar\ whereas, some study has earlier been done o\er the 
genotoxicity of the third drug Trental" . 
Pentoxifylline (PTX), a derivative of methylxanthine is an 
oxohexyl-substituted analogue of theobromine. Its chemical formula 
is (3. 7-dimethyl-l-[5-oxo-hexyl] xanthine). Isoxsuprine, or 
Isoxsuprine hydrochloride, is a beta agonist drug used as a vasodilator 
in humans and equines. Its chemical formula is 2-h}droxy-2-(4-
methoxyphenyl)-l-methyl-N-(l-phenoxy- 2-propyr) ethanaminium 
chloride. Xanthinol nicotinate is a peripheral vasodilator (nictonic 
acid prodrug). It is the most potent form of niacin (active part of 
vitamin B3). Its chmical formula is 7-[2-Hydroxy-3-(2-hydroxyethyl-
methyl-amino) propyl]-!, 3-dimethyl-purine-2, 6-dione pyridine-3-
carboxyiic acid. Metoprolol tartrate is an antihypertensive drug. It is a 
selective betal-adrenoreceptor blocking agent. It,s chemical formula 
H 
is l-Isopropylamino-3-[4- (2-methoxyethyl) phenoxy]-2-propanol L-
(+)-tartrate. 
Two highly rehable short-term genotoxicity assays, nameh 
chromosomal aberration (CA) assay and cytochalasin-blocked 
microiiucleus (CBMN) assay, were employed to test drug 
genotoxicity and cytotoxicity. Different concentrations of the drugs 
were used for the study and assay parameters like chromosomal 
aberrations, micronucleus frequencies, frequency of binucleated 
mirconucleated cells, nucleoplasmic bridge and nuclear bud 
frequencies, ratios of apoptotic and necrotic cells and cell c}cie 
kinetics, were employed to assess and evaluate the results. Values 
were compared with the concurrent controls and the statistical 
significance of the results was checked using Student's /-test and 2^3 
Chi-Square (-/') test. 
C»ur studies show that all these four test drugs significanth 
induce changes in the applied parameters, at different concentrations. 
Significantly high chromosomal aberration frequencies were obtained 
at 48 hour of incubation in chromosomal aberration assa\s. The 
highest response was observed in Isoxsuprine hydrochloride. Rest of 
the three drugs (Pentoxifylline, Xanthinol nicotinate and Metoprolol 
tartrate) also gave positive results. Structural chromosomal changes 
were mainly chromatid-type suggesting the clastogenic nature of the 
test drugs. Prevalence of chromatid-type structural changes suggested 
the S-phase dependent nature of these drugs. 
Increased drug induced frequencies of micronuclei were 
analyzed in CBMN assay. The liighest values were obtained tor drugs 
Xanthinol nicotinate and Pentoxifylline. This indicated thai the test 
drugs are potent inducers of chromosomal breakage and loss in 
cultured cells. Frequencies of nucleoplasmic bridges and nuclear buds 
were also increased with increased drug doses at 24 hour of 
incubation, suggesting chromosome rearrangement and gene 
amplification potency of these drugs. Xanthinol nicotinate was highly 
responsive for these parameters. The other three drugs also ga\e 
positive results. 
Data for the result of cell division kinetics showed reduced 
values for parameters like nuclear division index (NDI) and nuclear 
division cytotoxicity (NDCI) index, for the four test drugs. Reduction 
in the NDI and NDCI values indicated that the selected drugs 
disturbed cell-proliferation kinetics and induced cellular toxicity. 
As regards the comparative scale of toxicity induced in human 
lymphocytes, structural basis of mechanism of action could not be 
deducea, as the scope of the study is primarily the toxicit\ assa> 
rather than the mechanism of toxicity induced. This can be taken up in 
future studies with wider experimental designs. Summing up, the four 
selected vasodilator antihypertensive drugs showed some genotoxic 
potential it}' at applied concentrations in vitro in human cultured 
lymphocytes and thus required extensive evaluation for in vivo studies 
also. Their prolonged use may cause some serious side effects in the 
patients. 
ANALYSIS OF GENOTOXIC EFFECTS OF CERTAIN CLINICALLY 
USED VASODILATOR DRUGS ON HUMAN GENOME 
THESIS 
SUBMITTED FOR THE AWARD OF THE DEGREE OF 
Boctor of |^I)iIo!s;opI)p 
IN 
ZOOLOGY 
^ 
- t . . f f 
•^y 
BY 
Asma Fcirhat Sherwani 
SECTION OF GENETICS 
DEPARTMENT OF ZOOLOGY 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH (INDIA) 
2008 
oll.•,^N• 2013 
'D'E'DICJArtl'D 
TO 
_. f External : 2700920/21-3430 
Phones I,^jg^^g, .3430 
D E P A R T M E N T O F Z O O L O G Y 
AUGARH MUSLIM UNIVERSITY 
^ ,. ALIGARH-202002 
Sections: in. 11^1 A 
1. ENTOMOLOGY INDIA 
2. FISHERY SCIENCE & AQUACULTURE 
3. GENETICS -, , n, nCX 
4. NEMATOLOGY OdXwi .&M..^U^L&.... 
5. PARASITOLOGY ' 
D.No J ID. 
CERTIFICATE 
I feel great pleasure to forward the thesis entitled "Analysis of genotoxic 
effects of certain clinically used vasodilator drugs on human genome" 
for the degree of Doctor of Philosophy in Zoology (Genetics) of the Aligarh 
Muslim University, Aligarh. This thesis, as presented by Ms. Asma Frahat 
Sherwani, consists of subject matter which is the original record of work 
done by her under my supervision, and the same is not a part of any other 
course or degree presented to or taken by her. 
Mohammaa Afzal 
(Professor) 
TABLE OF CONTENTS 
CHAPTER SECTIONS PAGF NO 
Acknowledgement 1 
List of Tables ii-jii 
List of Figures iv-\j 
INTRODUCTION 1-38 
DNA DAMAGE 2 
- Sources of damage 
Types of damage 3 
DNA DAMAGE AND MUTATION 4 
DNA REPAIR MECHANISMS .^  
Direct reversal ^^  
Single strand damage 5 
Double- strand breaks 6 
Translesion synthesis 
DNA DAMAGE CHECKPOINTS 7 
THE PROKARYOTIC SOS RESPONSE 8 
EUKARYOTIC TRANSCRIPTIONAL RESPONSES TO DNA DAMAGE 8 
DNA REPAIR AND CANCER 8 
CHROMOSOMAL ABERRATIONS IN RELATION TO GENOTOXICITY 9 
Structural aberrations 9 
- Numerical aberrations 11) 
CLASSIFICATION OF PRIMARY CHANGES 1 (i 
- Chromosome-type 1 l 
- Chromatid-t}pe 11 
Relationship to the cell cycle 1 4 
SECONDARY OR DERIVED ABERRATIONS 1 .^  
CYTOGENETIC EFFECTS AND CELL DEATH / 7 
Necrosis 18 
Apoptosis 1 s 
AN INTRODUCTION TO MUTAGENICITY. CARCINO(.ENI( rrv \ \ ! ) 
GENOTOXICITY |4 
BIOCHEMICAL MECHANISMS OF MUTAGENESIS 20 
GENOTOXICITY TESTING 22 
Principle of genotoxicit}'testing 2? 
The standard Test Batten' for genotoxicit} 24 
SHORT TERM ZV VITRO GENOTOXICITY ASSAYS USED TO DETERMINE 
GENOTOXICITY OF TEST CHEMICALS 2^ 
Chromosomal aberration assay 2^ 
Micronacleus assay 28 
- Sister C hromatid Exchange assay 29 
EVALUATION OF GENOTOXICITY IN PHARMACEUTICALS 3 I 
HYPERTENSION 31 
CYTOGENOTOXIC EFFECTS OF CARDIOVASCULAR DRUGS - AN INSIGHT 
OBJECTIVES AND LIMITATIONS OF THE PRESENT WORK 3'T 
MATERIALS AND METHODS 39-54 
DESCRIPTION OF TEST DRUGS 40 
DESCRIPTION OF CONTROL CHEMICALS 4> 
MATERIALS 4h 
Chemicals and biochemials 46 
Test drugs and solvent controls 46 
Solutions and buffers 46 
Software 47 
METHODS 4" 
In vitro testing of chromosomal aberrations (CA assay) 4"^  
In vitro cytokinesis-blocked micronucleus (CBMN) assay 5 1 
Cell division kinetics 52 
Statistical evaluation of the test results 53 
RESULTS 55-114 
PENTOXIFYLLINE ( T R E N T A L " ) -^  
ISOXSUPRINE HYDROCHLORIDE ( D U V A D I L A N ' ) (.(i 
XANTHINOL NICOTINATE (COMPLAMINA') s 
M E T O P R O L O L T A R T R A T E ( M E T O L A R ' ) wj 
COMPARATIVE ANALYSIS OF THE PENTOXIFYLLINE. IS0XSlPRI\[ 
HYDROCHLORIDE. XANTHINOL NICOTINATE AND METOPROLOL TARTRATE I 0" 
DISCUSSION 115-130 
SELECTION OF TEST DRUGS I I > 
GENERAL CONSIDERATIONS 1 1 n 
EVALUATION OF TEST SYSTEMS 1 i n 
EVALUATION OF THE PARAMETERS ASSAYED I I •» 
CYTOGENETIC EFFECTS OF THE VASODILATOR ANTIHYPERTLNSI\ E DRlGs /\ 
VITRO. i : i 
PHOTOMIC ROGRAPHS 
BIBLIOGRAPHY 131 
ACKNOWLEDGEMENT 
My deepest thanks are due to Almighty whose will and support is the 
prime source of the completion of this work. 
I would, than, like to express my sincere thanks to Professor 
Mohammad Afzal, Head and Professor, Section of Genetics, Department of 
Zoology, Aligarh Muslim University, Aligarh, for his supervision, guidance 
and cooperation to complete this work. 
I would also like to thank my former supervisor, Dr. Md. Asim 
Azfer, who helped me start the work, but had to leave to go abroad to do 
some extensive research, and could not continue the supervision of my 
present work. 
Words are also worth-mentioning to Professor Absar Mustufa 
Khan, Chairman, Department of Zoology, Aligarh Muslim Universit\, 
Aligarh, for providing me necessary facilities for my research work. 
I am also thankful to Professor Waseem Ahmad Faridi, Dr. Anjum 
Ara and Dr. GGHA Shadab, teachers in the Section of Genetics, who were 
the source of inspiration for me. 
My sincere thanks to Professor Irfan Ahmad who permited me and 
helped in getting photomicrographs of the slides concerning my work in his 
laboratory. 
I would be failing in my duties if I would not thank Ms. Fauzia Khan 
and Dr. Mumtaz Jabeen, my lab colleagues and friends, whose help and 
support was vital for me. I owe my thanks to my other colleagues also. 
Last, but not least, I also want to thank all the non-teaching staff of the 
department for their valuable support. 
ASMA FARHAT SHERWANI 
LIST OF TABLES 
FABLE NO. TITLE PAGE NO 
1. Chromosomal aberrations induced by Pentoxifylline in cultured human 
peripheral blood lymphocytes. 6D 
2. Estimation of frequencies of Pentoxifylline induced micronuclei in human 62 
lymphocytes in vitro. 
3. Frequencies of binucleated cells with nucleoplasmic bridges, micronuclei 6 3 
and nuclear buds observed after the treatment Pentoxifylline at different 
concentrations in human lymphocytes in vitro. 
4. Estimation of nuclear division index (NDI) for 500 viable cells after the 65 
treatment of different concentrations Pentoxifylline in vitro. 
5. Estimation of nuclear division c>totoxicity index (NDCI) for 500 (\iable - 66 
nonviable) cells after the treatment of different concentrations of 
Pentoxifylline m vitro. 
6. Chromosomal aberrations induced by Isoxsuprine hydrochloride in cultured 7;; 
human peripheral blood lymphocytes. 
7. Estimation of frequencies Isoxsuprine hydrochloride induced micronuclei in 75. 
human lymphocytes in vitro. 
8. Frequencies of binucleated cells with nucleoplasmic bridges, micronuclei 76 
and nuclear buds observed after the treatment Isoxsuprine hydrochloride at 
different concentrations in human lymphocytes in vitro. 
9. Estimation of nuclear division index (NDI) for 500 viable cells after the 78 
treatment of different concentrations of Isoxsuprine hydrochloride in vitro. 
10. Estimation of nuclear division cytotoxicity index (NDCI) for 500 (viable + 79 
nonviable) cells after the treatment of different concentrations of Isoxsuprine 
hydrochloride in vitro. 
11. Chromosomal aberrations induced by Xanthinol nicotinate in cultured human 86 
peripheral blood lymphocytes. 
II 
12. Estimation of frequencies of Xanthinol nicotinate induced micronuciei in 88 
human lymphocytes in vitro. 
13.Frequencies of binucleated cells with nucleoplasmic bridges, micronuciei 89 
and nuclear buds observed after the treatment of Xanthinol nicotinate at 
different concentrations in human lymphocytes in vitro. 
14.Estimation of nuclear division index (NDI) for 500 viable cells after the 9i 
treatment of different concentrations of Xanthinol nicotinate in vitro. 
15. Estimation of nuclear division cytotoxicity index (NDCI) for 500 (viable - 92 
nonviable) cells after the treatment of different concentrations of Xanthinol 
nicotinate in vitro. 
16. Chromosomal aberrations induced by Metoprolol tartrate in cultured human 99 
peripheral blood lymphocytes. 
17. Estimation of frequencies of Metoprolol tartrate induced micronuciei in ici 
human lymphocytes in vitro. 
18. Frequencies of binucleated cells with nucleoplasmic bridges, micronuciei 102 
and nuclear buds observed after the treatment of Metoprolol tartrate at 
different concentrations in human lymphocytes in vitro. 
19. Estimation of nuclear division index (NDI) for 500 viable cells after the 104 
treatment of different concentrations of the Metoprolol tartrate in vitro. 
20. Estimation of nuclear division cytotoxicity index (NDCI) for 500 (viable + 105 
nonviable) cells after the treatment of different concentrations of Metoprolol 
tartrate in vitro. 
21. Comparative analysis of averages of means (± SEM) of % aberrant n o 
metaphases and aberrations / cell in four test drugs. 
22. Comparative analysis of averages of means (± SEM) of % MN frequency. % m 
BNMN cell frequency, % BNNPB cell frequency and % BNNBcell 
frequency in four test drugs. 
23. Comparative analysis of averages of mean nuclear division index (NDI) and 113 
mean nuclear division cytotoxicity index (NDCI) values of four test drugs. 
I l l 
LIST OF FIGURES 
FIGURE NO. TITLE PAGE NO. 
1. Frequencies of aberrant metaphases plotted against different concentrations ^^  
of the drug Pentoxifylline. 
2. Dose-response curve of aberrations per cell in human lymphocytes in vitro 61 
treated with different concentrations of the Pentoxifylline. 
3. Dose-response curve of micronuclei frequencies in human lymphocytes in 64 
vitro treated with different concentrations of the Pentoxif>iline. 
4. Frequencies of binucleated micronucleated cells, nucleopiasmic bridges 64 
and nuclear buds in human lymphocytes in vitro plotted against different 
concentrations of Pentoxifylline. 
5. Dose-response curve of nuclear division indices in human lymphocytes in 67 
vitro treated with different concentrations of Pentoxifylline. 
6. Dose-response curve of nuclear division cvlotoxicit} indices in human 67 
lymphocytes treated with different concentrations Pentoxify lline in \ itro. 
7. Frequencies of aberrant metaphases plotted against different concentrations 74 
of the drug Isoxsuprine HCl. 
8. Dose-response curve of aberrations per cell in human lymphocytes in vitro 74 
treated with different concentrations Isoxsuprine HCl. 
9. Dose-response curve of micronuclei frequencies in human lymphocjtes in 77 
vitro treated with different concentrations Isoxsuprine HCl. 
10. Frequencies of binucleated micronucleated cells, nucleopiasmic bridges 77 
and nuclear buds in human lymphocytes in vitro plotted against different 
concentrations Isoxsuprine HCl. 
11. Dose-response curve of nuclear division indices in human lymphocytes in 80 
vitro treated with different concentrations Isoxsuprine HCl. 
12. Dose-response curve of nuclear division cytotoxicity indices in human 80 
lymphocytes in vitro treated with different concentrations Isoxsuprine HCl. 
IV 
13. Frequencies of aberrant metaphases plotted against different concentrations 87 
of the drug XanthinoJ nicotinate 
14. Dose-response curve of aberrations per cell in human lymphocytes in vitro 87 
treated with different concentrations Xanthinol nicotinate. 
15. Dose-response curve of micronuclei frequencies in human lymphoc>tes in 90 
vitro treated with different concentrations Xanthinol nicotinate. 
16. Frequencies of binucleated micronucleated cells, nucleoplasmic bridges 90 
and nuclear buds in human lymphocytes in vitro plotted against different 
concentrations Xanthinol nicotinate. 
17. Dose-response curve of nuclear division indices in human lymphocytes in 93 
\ itro treated with different concentrations Xanthinol nicotinate. 
18. Dose-response curve of nuclear division cytotoxicit>' indices in human 93 
lymphocytes in vitro treated with different concentrations Xanthinol 
nicotinate. 
19. Frequencies of aberrant metaphases plotted against different concentrations lOO 
of the drug Metoprolol tartrate. 
20. Dose-response curve of aberrations per cell in human lymphocytes in vitro lOO 
treated with different concentrations Metoprolol tartrate. 
21. Dose-response curve of micronuclei frequencies in human lymphocytes in 103 
vitro treated with different concentrations Metoprolol tartrate. 
22. Frequencies of binucleated micronucleated cells, nucleoplasmic bridges 103 
and nuclear buds in human lymphocytes in vitro plotted against different 
concentrations Metoprolol tartrate. 
23.Dose-response curve of nuclear division indices in human lymphocytes in 106 
vitro treated with different concentrations Metoprolol tartrate. 
24. Dose-response curve of nuclear division cytotoxicit\' indices in human 106 
lymphocytes in vitro treated with different concentrations Metoprolol 
tartrate. 
25. Average of mean frequencies of aberrant metaphases and aberrations/cell 112 
in 4 cardiovascular drugs plotted against different concentrations of all 4 
drugs. 
26. Average of mean frequencies of binucleated micronucleated cells. 112 
nucleoplasmic bridges and nuclear buds in four cardiovascular drugs 
plotted against different concentrations of all drugs. 
27. Dose-response curve of average mean nuclear division indices in human 114 
lymphocytes in vitro in four tested drugs treated with different drug 
concentrations. 
28. Dose-response curve of mean nuclear division cytotoxicity indices in 114 
human lymphocytes in vitro in four tested drugs treated with different drug 
concentrations. 
VI 
I!Nrr'ROVtlC7lO:N' 
The growing industrialization provide basic comforts and amenities to 
the human society, however it also exposes humans to the hazards of a 
variety of chemical substances, pollutants and harmful radiations. Interaction 
with the chemicals like medicinal products, food stuffs, environmental 
contaminents, pesticides, clothing apparels, daily-use commodities, cosmetic 
ranges, plastic and leather wares, and petrochemical products etc present in 
the environment, is frequent in different forms. 
It has now become evident that some of these chemicals can cause 
cancer in man. More recently, there has been a growing awareness of the 
possibilit}' that some chemicals may also produce mutations in human germ 
cells thus influencing the frequency of genetic or heritable diseases. There 
are many compounds that occur naturally, which are known to be mutagenic 
and/or carcinogenic (e.g., mycotoxins in foods). The extent to which human 
population is exposed to different types of environmental agents, chemicals 
and drugs is alarming. It is important, therefore, that chemicals to which 
people are exposed, either intentionally (e.g., therapeutically), routinely in 
the course of their daily life (e.g., in domestic products, cosmetics, etc.), or 
inadvertently (e.g., in pesticides) are tested for their potential to produce 
cancer or genetic damage, i.e., mutations (IPSC. WHO, 1985). 
Mutagenic chemicals interact with DNA causing changes in its 
structure. This may result in the loss, addition, or replacement of bases, thus 
altering their sequence in the DNA and affecting the fidelity of the genetic 
message. The effect of these mutational changes may be to prevent the 
synthesis of functional proteins completely (i.e., inhibition of gene 
expression) or may lead to the synthesis of proteins with modified structure 
and enzymes with altered activity and specificity. Where mutations lead to 
changes in the genetic information carried by male or female germ cells, the 
progeny of such affected parents may express the mutation as some form of 
heritable abnormality or disease. When mutations occur in the somatic cells 
of a complex organism, they may produce irreversible changes in the cell 
that may ultimately be involved in producing a cancerous growth (IPSC. 
WHO, 1985). 
Damage to DNA may be expressed as mutations at the chromosome 
level (i.e., chromosomal aberrations or chromosomal mutations) or at the 
level of the gene (i.e., gene or point mutations). Chromosomal mutations 
may be observed as changes in the structure of the chromosome (structural 
aberrations) or in the number of chromosomes in a cell (numerical 
aberrations or aneuploidy). Structural aberrations are a consequence of DNA 
damage while numerical changes are usually caused by defects in the 
accurate distribution of chromosomes during cell division, i.e., DNA damage 
may not be involved (IPSC. WHO, 1985). Mutations contribute significantly 
to human diseases and congenital malformations, though the extent of this 
contribution is not precisely known. For many years, the interaction of 
chemicals with the genetic material has been studied intensively (Singer and 
Kusmierek, 1982) with a view that the preservation of integrity of DNA as a 
genetic blueprint is of prime importance for any living organism. 
DNA DAMAGE 
DNA damage, due to environmental factors and normal metabolic 
processes inside the cell, occurs at a rate of 1,000 to 1,000,000 molecular 
2 
lesions per cell per day (Lodish, et al., 2004). The vast majority of DNA 
damage affects the primary structure of the double helix; that is, the bases 
themselves are chemically modified. 
Sources of damage 
The source of DNA damage can be subdivided into two main types: 
• Endogenous damage such as attack by reactive oxygen species 
produced from normal metabolic byproducts (spontaneous mutation), 
especially the process of oxidative deamination. 
• Exogenous damage caused by external agents such as ultraviolet 
radiation from the sun, other radiation frequencies (X-rays and gamma 
rays etc.), hydrolysis, certain plant toxins, mutagenic chemicals and 
cancer chemotherapy and radiotherapy. 
Types of damage 
There are four main types of damage to DNA due to endogenous 
cellular processes: 
• Oxidation of bases and generation of DNA strand interruptions from 
reactive oxygen species. 
• Alkylation of bases (usually methylation). 
Hydrolysis of bases, such as deamination, depurination and 
depyrimidination. 
Mismatch of bases, due to errors in DNA replication. 
Damage caused by exogenous agents occurs in many forms, such as: 
3 
• 
• 
• 
UV-B light causes crosslinking between adjacent cytosine and 
thymine bases creating pyrimidine dimers. This is called direct DNA 
damage. 
UV-A light creates mostly free radicals. The damage caused by free 
radicals is called indirect DNA damage. 
Ionizing radiation causes breaks in DNA strands. 
Thermal disruption at elevated temperature increases the rate of 
depurination and single strand breaks. 
Industrial chemicals and environmental chemicals create a huge 
diversity of DNA adducts- ethenobases, oxidized bases, alkylated 
phosphotriesters and crosslinking of DNA etc. 
DNA DAMAGE AND MUTATION 
DNA damage and mutation are two major types of error in DNA 
which are fundamentally different from each other. Damages are physical 
abnormalities in the DNA, such as single and double strand breaks and 
polycyclic aromatic hydrocarbon adducts. These damages can be recognized 
by enzymes, and thus they can be correctly repaired if redundant 
information, such as the undamaged sequence in the complementary DNA 
strand or in a homologous chromosome, is available for copying. If a cell 
retains DNA damage, transcription of a gene can be prevented and thus 
translation into a protein will also be blocked. Replication may also be 
blocked and/or the cell may die. 
In contrast to DNA damage, a mutation is a change in the base 
sequence of the DNA. A mutation cannot be recognized by enzymes once 
the base change is present in both DNA strands, and thus a mutation cannot 
be repaired. At the cellular level, mutations can cause alterations in protein 
function and regulation. Mutations are copied when the cell replicates. 
Although distinctly different from each other, DNA damages and 
mutations are related because DNA damages often cause errors of DNA 
synthesis during replication or repair and these errors are a major source of 
mutation. DNA damages in frequently dividing cells are a prominent cause 
of cancer. In contrast, DNA damages in the infrequently dividing cells are 
likely to be a prominent cause of aging. 
DNA REPAIR MECHANISMS 
Cells cannot function if DNA damage corrupts the integrit>' and 
accessibility of essential information in the genome. Depending on the type 
of damage inflicted on the DNA's double helical structure, a variety of repair 
strategies have evolved to restore lost information. 
Direct reversal 
Cells are known to eliminate three types of damage to their DNA b\' 
chemically reversing it. These mechanisms do not require a template, since 
the types of damage they counteract can only occur in one of the four bases. 
Such direct reversal mechanisms are specific to the type of damage incurred 
and do not involve breakage of the phosphodiester backbone. 
Single strand damage 
When only one of the two strands of a double helix has a defect, the 
other strand can be used as a template to guide the correction of the damaged 
strand. In order to repair damage to one of the two paired molecules of 
DNA, there exist a number of excision repair mechanisms that remove the 
damaged nucleotide and replace it with an undamaged nucleotide 
complementary to that found in the undamaged DNA strand (Watson, et al. 
2004). 
• Base excision repair (BER), which repairs damage to a single 
nucleotide caused by oxidation, alkylation, hydrolysis, or 
deamination. 
• Nucleotide excision repair (NER), which repairs damage affecting 
longer strands of 2-30 bases. 
• Mismatch repair (MMR), which corrects errors of DNA replication 
and recombination that result in mispaired nucleotides following DNA 
replication. 
Double-strand breaks 
Double-strand breaks (DSBs), in which both strands in the double 
helix are severed, are particularly hazardous to the cell because they can lead 
to genome rearrangements. Two mechanisms exist to repair DSBs (Watson, 
et al. 2004): 
(i) Non-homologous end joining (NHEJ) and 
(ii) Recombinational repair (also known as template-assisted repair or 
homologous recombination repair). 
In NHEJ, DNA ligase IV, a specialized DNA ligase, directly joins the 
two ends (Wilson, 1997). NHEJ can also introduce mutations during repair. 
Loss of damaged nucleotides at the break site can lead to deletions, and 
joining of nonmatching termini to form translocations. NHEJ is important 
especially before the cell has replicated its DNA, since there is no template 
available for repair by homologous recombination. 
Recombinational repair requires the presence of an identical or nearly 
identical sequence to be used as a template for repair of the break. The 
enzymatic machinery responsible for this repair process is nearly identical to 
the machinery responsible for chromosomal crossover during meiosis. This 
pathway allows a damaged chromosome to be repaired using a sister 
chromatid (available in G: after DNA replication) or a homologous 
chromosome as a template. 
Translesion synthesis 
Translesion synthesis is a DNA damage tolerance process that allows 
the DNA replication machinery to replicate past DNA lesions such as 
thymine dimers or AP sites. It involves the switching out of regular DNA 
polymerases for specialized translesion polymerases, often with larger active 
sites that can facilitate the insertion of bases opposite damaged nucleotides. 
DNA DAMAGE CHECKPOINTS 
After DNA damage, cell cycle checkpoints are activated. Checkpoint 
activation pauses the cell cycle and gives the cell time to repair the damage 
before continuing to divide. DNA damage checkpoints occur at the G|/S and 
G2/M boundaries. An intra-S checkpoint also exists. 
THE PROKARYOTIC SOS RESPONSE 
The LSOS response is the term used to describe changes in gene 
expression in Escherichia coli and other bacteria in response to extensive 
DNA damage. The prokaryotic SOS system is regulated by two key 
proteins: LexA and RecA. The LexA homodimer is a transcriptional 
repressor that binds to operator sequences commonly referred to as SOS 
boxes. The most common cellular signals activating the SOS response are 
regions of single stranded DNA (ssDNA), arising from stalled replication 
forks or double strand breaks, which are processed by DNA helicase to 
separate the two DNA strands (Friedberg, et al., 1995). 
EUKARYOTIC TRANSCRIPTIONAL RESPONSES TO DNA 
DAMAGE 
Eukaryotic cells exposed to DNA damaging agents also activate 
important defensive pathways by inducing multiple proteins involved in 
DNA repair, cell cycle checkpoint control, protein trafficking and 
degradation. Such genome wide transcriptional response is very complex 
and tightly regulated, thus allowing coordinated global response to damage. 
In an animal different types of cells are distributed amongst different organs 
which have evolved different sensitivities to DNA damage (Fry, et al., 
2004). 
DNA REPAIR AND CANCER 
Inherited mutations that affect DNA repair genes are strongly 
associated with high cancer risks in humans. BRCAl and BRCA2, two 
famous mutations conferring a hugely increased risk of breast cancer on 
carriers, are both associated with a large number of DNA repair pathways, 
especially NHEJ and homologous recombination. 
Cancer therapy procedures such as chemotherapy and radiotherap> 
work by overwhelming the capacity of the cell to repair DNA damage, 
resulting in cell death. Cells that are most rapidly dividing, typically cancer 
cells, are preferentially affected. The side effect is that other non-cancerous 
but rapidly dividing cells such as stem cells in the bone marrow are also 
affected. Modem cancer treatments attempt to localize the DNA damage to 
cells and tissues only associated with cancer, either by physical means 
(concentrating the therapeutic agent in the region of the tumor) or by 
biochemical means (exploiting a feature unique to cancer cells in the body). 
CHROMOSOMAL ABERRATIONS IN RELATION TO 
GENOTOXICITY 
There are various classes of chromosomal changes that can be induced 
by exposure to chemical substances. These changes, also known as 
chromosomal aberrations, are either structural changes in chromosomal 
shapes or numerical changes in chromosomal counts. 
A. Structural aberrations 
Following changes are involved in chromosome structure: 
Gaps: Unstained regions that are smaller than the diameter or width of the 
chromatid. The chromatids do not show any misalignment. 
Breaks: Damage to the chromatid or isochromatid involving a discontinuit} 
of the chromosomes greater than the width of the chromatid. It may be 
accompanied by a misalignment of the chromatids or chromosomes. 
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Dicentric Chromosomes: These are chromosomes with two centromeres 
with or without associated fragments. 
Ring Chromosomes: aberrant circular chromosomes resulting from the 
joining of two breaks on separate arms of the same chromosome (generally 
accompanied by an acentric fragment). They are also called centric rings. 
B. Numerical aberrations 
Changes in the chromosome count is referred to as Polyploidy, a 
condition in which cells display more than double the chromosome number 
(2n) exact multiples of the haploid chromosome numbers. 
• polyploidy (4n) 
• hypodiploidy (< 46chr) 
• hyperdiploidy (> 46chr) 
Visible changes to chromosome structure and morphology have 
played a very important part as indicators of genetic damage in both clinical 
and cancer studies. Most of the changes encountered in clinical studies are 
"secondary" or "derived" aberrations (Savage, 1999) 
Primary aberrations are those seen at the first post-induction division, 
when all the parts are present and there has been no selection by passage 
through mitosis, nor any modification by subsequent chromosome 
duplication (Savage, 1976) 
CLASSIFICATION OF PRIMARY CHANGES 
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Since the chromosome at metaphase has two (sister-) ciiromatids, it is 
convenient (and conventional) to divide all aberrations into two broad types 
(Savage, 1999): 
Chromosome-type where the breaks and re-joins always affect both sister-
chromatids of a chromosome at any one locus. They are also referred to as 
an isochromatid aberrations (Figure A). 
Chromatid-type where the breaks and re-joins affect only one of the two 
sister-chromatids of a chromosome at any one locus (Figure B). 
Following an "acute" treatment with any clastogen, surviving cells in 
later generations carry only chromosome-type changes. The presence of 
chromatid-type aberrations in such cells is, therefore, an indicator of an 
ongoing production of primary structural changes, i.e. of some form of 
chromosome instability (Savage, 1999) 
Nearly all the aberrations appear to result from the interaction (re-
joining) of two breaks, so they can be further classified on the basis of where 
these breaks are situated in relation to the chromosome arms (Savage, 1976) 
If the breaks are situated in the arms of different (non-homologous or 
homologous) chromosomes, they come under the category of interchanges. 
• If the breaks are in the opposite arms of the same chromosome, they 
came under the category of inter-arm intrachanges. 
• If the two breaks are both in the same arm of a chromosome, they 
came under the category of intra-arm intrachanges. 
These three categories are often referred to collectively as Exchanges. 
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Figure A. Chromosome - type aberrations (Savage, 1999) 
(A-asymmetric, S-symmetric). 
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Figure B. Chromatid - type aberrations (Savage, 1999) 
(A-asymmetric, S-symmetric). 
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Finally, some aberrations appear to arise from a single, open break in 
just one arm. This category is termed as breaks or discontinuities. Man\ of 
them are, in reality, intra-arm intrachanges where one end has failed to join 
up properly. 
Many chromosome-type aberrations which are scored as "simple" 
two-break interactions actually involve more than two breaks, and often 
more than two chromosomes, i.e. they are complex exchanges (Savage, and 
Harvey, 1994). 
During the process of re-joining of breaks, interaction between the 
four ends of two breaks takes place in three ways: 
a. Join back to re-form the original chromosomes (restitution) so that no 
aberration is produced. 
b. Re-join in such a way that an acentric fragment is always formed 
(asymmetrical re-joining). Asymmetrical aberrations are almost always 
cell-lethal, and so rapidly disappear from a population of continuously 
dividing cells (Lea, 1955; Savage, 1989). 
c. Re-join in a way that never leads to an acentric fragment unless one of 
the re-joins is incomplete (symmetrical re-joining). Because there is no 
loss of genetic material, and no mechanical problems at mitosis, most 
symmetrical forms are transmissible to future cell generations (Savage, 
1976, 1995). 
As mentioned, re-joining can sometimes be (apparently) incomplete. 
This is much more frequent for chromatid-type aberrations (typically 30-
50% of interchanges) as compared to chromosome-type aberrations (difficult 
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to measure accurately, but probably around 3-5%). Incompleteness leads to 
genetic loss, and so to increased cell lethality. 
The four basic categories discussed above are seen in their simplest 
forms for chromosome-type aberrations, as shown in Figure B. 
Because sister-chromatids tend to adhere, strongly, along their 
lengths, many chromatid-type symmetrical forms remain visible without 
recourse to special staining methods, as Figure 2 shows. Moreover, the 
presence of sister-chromatids allows additional lesion interactions {inter-
chromatid, intra-arm intrachanges) not possible with chromosome-type 
changes. As a consequence, there is a much higher frequency of chromatid-
type changes, and a much greater variety of forms, compared with 
chromosome-types, following a given treatment. Moreover, the interactions 
within chromosome arms which are now possible make chromatid-npe 
aberrations a much more likely source of the complicated 
duplications/deletions etc. encountered in clinical and cancer studies. 
Combinations of the various categories are frequent, especially for 
chromatid-types {interchange/intra-arm intrachange) giving rise to 
configurations like triradials (Savage and Harvey, 1994), but these, of 
course, constitute a type of complex exchange. Surviving remnants of such 
events are responsible for some of the curious anomalies recorded in clinical 
and cancer cell studies. 
Relationship to the cell cycle 
Conventionally, the period between successive mitoses (interphase) is 
sub-divided into three phases Gi, S and G2. For experimental work, further 
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sub-division of S is possible (Savage, et al., 1984) Gl is the pre-duplication 
period, when the cell begins to prepare for DNA synthesis and the next 
mitosis. S-phase is a discrete period of interphase of a few hours duration 
during which the chromosomal DNA and protein is duplicated, and the new 
chromatin segregated into the sister-chromatids. If the cell is not going to 
divide again, it passes out of cycle during this phase into another phase 
termed GQ. From this phase it may, or may not, be possible to call it back 
into a division cycle. Usually, however, cells pass on to irreversible 
differentiation with their chromosomes unduplicated. 
Most aberration-inducing agents can introduce lesions into the 
chromatin at all stages of the cell cycle, but relatively few of them can 
produce actual structural changes in Gi,( and therefore give rise to primary 
chromosome-ty-pe changes) or in S and G2 (producing primary chromatid-
types ). Ionising radiation, restriction endonucleases, and a few chemicals 
like bleomycin and some antibiotics are amongst those that can produce such 
changes. Almost all remaining aberration producing agents are S-dependent. 
Surviving unrepaired lesions from Gi or G2 have to pass through a scheduled 
S-phase to convert them into exclusively chromatid-type aberrations. 
SECONDARY OR DERIVED ABERRATIONS 
Although there is an enormous range of primary aberration forms, 
very few of them are transmissible to future cell generations long term, so 
only some secondary (or derived) forms are recovered (Savage, 1976; 
Savage, 1995). Various types of secondary changes are categorized as: 
/. Reciprocal translocation: 
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These changes are derived directly from chromosome-type reciprocal 
translocations or from one segregation sequence of symmetrical chromatid-
type interchanges. They do not involve any mechanical separation problems 
at anaphase, and usually no genetic loss or imbalance. 
//. Pericentric Inversion : 
These changes are derived directly from chromosome-type or 
chromatid-type pericentric inversions. They have properties very similar to 
those for reciprocal translocations. Large inversions lead to meiotic bridges, 
sterility and cell death. 
/•//. Paracentric inversion : 
These changes are derived directly from chromosome-type paracentric 
inversions, or from one form of chromatid-type intra-chromatid intra-arm 
intrachange. They are very difficult to detect at the chromosome level unless 
they are very large (many megabases of DNA). Again the re-joining points 
can disrupt important genetic sequences, and reverse segments of the reading 
frame. Large inversions will give problems at meiosis. 
/v. Interstitial deletion: 
These changes are derived directly from chromosome-type interstitial 
deletions (double minutes) and from the alternative form of chromatid-type 
intra-chromatid intra-arm intrachange to that which produces paracentric 
inversions. Segregation products from some complex chromatid-type 
interchanges can also carry deletions. 
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The loss of small segments of a chromosome (usually only in one 
homologue) is not uncommon. Very occasionally, the loss of quite large 
segments appears to be compatible with cell survival. 
V. Terminal deletion: 
Derivation of terminal deletion, if genuine, is from various forms of 
incomplete chromosome-type or chromatid-type intrachanges and 
interchanges, followed by telomerase activity to achieve capping. It is not 
known whether true stable terminal deletions actually exist. 
vL Interstitial duplication: 
These changes are most likely derived from one form chromatid-type 
inter-chromatid intra-arm intrachange. Some forms of complex chromatid-
type interchanges can segregate to give surviving chromosomes with 
duplicated segments. Segments of a chromosome repeat in tandem. 
sometimes in reverse sequence. 
viu Interstitial insertion: 
All insertions are derived from complex exchanges, since, by 
definition, their production requires the interaction of a minimum of 3 
lesions. In the formation of these changes, either chromosome-ty^pe or 
chromatid-type, complex interchanges may be involved, the range of inter-
intrachanges in the latter is particularly productive of insertions. 
CYTOGENETIC EFFECTS AND CELL DEATH 
Genotoxic behavior, of some potent DNA-damaging agents causes 
genotoxic stress-induced cell destruction. Cell death occurs by one of two 
17 
mechanisms - necrosis or apoptosis. These are two physiologically different 
processes. Necrosis is death by injury and apoptosis is death by suicide. 
Both of these mechanisms have different characteristics. 
Necrosis 
Necrosis is cell death by accident. It is associated with 
nonphysiological circumstances that disrupt cellular homeostasis (eg, 
ischemia, hypoxia and poisoning). Necrosis is caused by membrane 
dissolution (osmotic lysis, shear stress, pore-forming proteins, loss of ATP). 
This phenomenon is harmful for cell viability because cellular material 
(including degradative enzymes) is released into surrounding tissue resulting 
into inflammatory reactions. This affects contiguous groups of cells. 
Necrotic cell death is characterized by nuclear swelling, cell swelling, 
disruption of organelles, and rupture of cell and release of cellular contents, 
which results into inflammatory response. 
Apoptosis 
Apoptosis is genetically programmed self - destruction of 
autoreactive or damaged cells (Kerr, et al, 1972; Wyllie, et al, 1980). Cell 
destruction is induced by new gene synthesis, primarily in response to 
developmental cues. It requires new RNA and protein synthesis. Inhibitors 
of transcription or translation prevent apoptosis. It is important for 
development, homeostasis and elimination of pathogens and tumor cells. It 
causes deletion of individual cells in the midst of others. But it can be 
involved in deletion of entire structures also. Apoptosis is followed by fast 
phagocytosis, and it is anti-inflammatory (housekeeping). Activation of 
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apoptosis in cells is initiated by various types of DNA damages (Kerr, et ai, 
1972; Wyllie, e/fl/., 1980). 
The symptoms of apoptosis, or programmed cell death, are viability 
loss accompanied by chromatin condensation, membrane blebbing, cell 
shrinkage, and packaging of nuclear fragments into small apoptotic bodies 
(Kerr, et al, 1972; Wyllie, et al, 1980). 
Regulation of cell death is essential for normal development and 
elimination of cells that have suffered serious damage and it is an important 
defense against the emergence of cancer and other diseases. Perturbations of 
apoptosis contribute to the pathogenesis of several human diseases including 
cancer, acquired immunodeficiency syndrome and neurodegenerative 
disorders (Thompson, 1995). 
AN INTRODUCTION TO MUTAGENICITY, CARCINOGENICITY 
AND GENOTOXICITY 
Mutations are permanent hereditary changes in the cell lines, either 
horizontally in the somatic cells or vertically in the germinal cells of the 
body. That is, mutations may affect the organism itself through changes in 
body cells, or they may be passed on to other generations through alteration 
of the sex cells. Genotoxicity thus precedes mutagenicity although most of 
genotoxicity is repaired and is never expressed as mutations. Somatic 
mutations are induced at the cellular level and in the event that they lead to 
cell death or malignancies, may become manifest as various disorders of 
tissues or of the organism itself Somatic mutations are thought to be related 
to ageing effects or to the induction of atherosclerotic plaques. 
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Although there is no definitive evidence that exposure to chemicals is 
responsible for any of the known human genetic disorders, experimental 
evidence from other mammals have shown that chemicals can produce both 
chromosomal and gene mutations of the type that are associated with human 
genetic diseases. There is little direct evidence to suggest that man is any 
less susceptible than other mammals to the effects of exposure to mutagenic 
chemicals. Alterations in the structure and function of DNA are believed to 
play a crucial role in the production of cancer by chemicals. Carcinogenesis 
is a multistage process that may take years to evolve and a number of 
different factors influence the progression from a normally functioning cell 
to an invasive neoplastic tumour. The animal bioassay for detecting 
carcinogenic chemicals is a prolonged and very expensive scientific study 
using some hundreds of rodents to which the suspect chemical is 
administered for most of their life span. Similarly, the specific locus test in 
mice (Searle, 1975), which is one of the few currently available assays for 
detecting heritable gene mutations in mammals, requires the examination of 
many thousands of offspring and is equally expensive and time-consuming. 
Thus, of the multitude of chemicals introduced into the environment in this 
century, and the hundreds of new compounds being synthesized each year, 
only a small fraction can be tested in conventional animal studies. For this 
reason, the last decade has seen the introduction of a number of relatively 
rapid tests for detecting mutagenic and carcinogenic chemicals. Such tests 
are economical in resources and produce results in a matter of weeks. 
Almost all of these short-term procedures are based on the demonstration of 
chromosomal damage, gene mutations, or DNA damage, and many of them 
are in vitro assays. The test organisms range from bacteria and yeasts to 
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insects, plants, and cultured animal cells, there are also short-term tests in 
which laboratory animals are exposed to test chemicals for periods of a few 
hours to, at most, a few weeks. Mammalian cell cultures provide a 
convenient test system and either established cell lines or human blood 
lymphocytes can be used in practice, a suspect chemical is first tested using 
in vitro procedures, to study its ability to react with DNA and thus induce 
mutations. It may then be necessary to determine its genotoxicity for intact 
animals by testing in short-term mammalian {in vivo) assays. 
BIOCHEMICAL MECHANISMS OF MUTAGENESIS 
Chemical carcinogens and mutagens act by chemically modifying the 
bases in DNA, particularly guanine. There are two sites on the guanine 
molecule to which groups can easily be covalently attached in the presence 
of reactive metabolites of chemical carcinogens, namely the O,. and N-
positions. Substitution at the O^ position of guanine is most sensitive to 
produce a permanent mutagenic effect which is perpetuated when the DNA 
is replicated, whereas N7 substitutions are usually quickly repaired by the 
normal DNA repair mechanisms involving excision and replacement of 
altered base. 
The accessibility of DNA bases to chemical attack is more when the 
DNA is in the process of replication. The likelihood of genetic damage by 
many mutagens is related to the frequency of cell division. This means that 
the developing focus is particularly susceptible, and thus many mutagens 
and carcinogens are also teratogenic. Some mutagens, particularly ionizing 
radiations, can affect DNA whether or not it is replicating, so that even the 
female germ cells are sensitive throughout their reproductive life. 
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GENOTOXICITY TESTING 
Genotoxicity is defined as an organism-specific and quantitative 
measure of the potential of a specific chemical or of electromagnetic 
environment to cause damage to the DNA of a cell (Corbisier, and Barcelo. 
2000). The Mutagenic Index (MI) is binary value of 1 or 0 that is assigned to 
a compound, where 1 indicates a mutagen (positive) and 0 indicates a non-
mutagen (negative). Mutagenicity is an effect that occurs when cellular 
DNA is altered as a result of its interaction with a chemical entity. DNA may 
be altered by interaction with a drug in several ways, such as the formation 
of a covalent bond between the drug and the DNA. The result of the 
formation of such a covalent bond is a specific adduct or physical alteration 
of DNA which may lead to such complications as nucleotide strand breakage 
or the disruption replication or translation. The three principal classes of 
drug interactiori with DNA are intercalators, alkylators, and DNA strand 
breakers. Most of these effects are the result of irreversible binding of the 
drug to that DNA and all three modes of interaction have mutagenic 
consequences. Genotoxic chemicals are generally electrophilic in nature 
either directly, or through microsomal activation (S9), which results in the 
ability of the chemical to react with DNA through alkylation. Further, 
genotoxic changes can also occur indirectly with non-electrophilic entities, 
which interfere with molecules or enzymes associated with DNA synthesis 
or chromosomal segregation. Therefore, genotoxic compounds may act 
directly or indirectly on DNA to produce non-lethal, but harmful heritable 
changes in the structure or arrangement of genes (Corbisier, and Barcelo 
2000). 
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Genotoxicity testing of New Chemical Entities (NCE) is generally 
used for hazard identification with respect to DNA damage and its fixation 
(Madle, et al., 1987). These damages can be manifested in the form of gene 
mutation, structural chromosomal aberration, recombination, and numerical 
changes. These changes are responsible for heritable effects on germ cells 
and impose risk to future generations (Wassom, 1992). In addition it has 
been well documented that somatic mutations can also play an important 
role in malignancy (Tennant, et al., 1987). These tests have been used 
mainly for the prediction of carcinogenicity and genotoxicity because 
compounds, which are positive in these tests, have the potential to be human 
carcinogens and/or mutagens (Jena, et al., 2002). 
The outcome of genotoxicity tests are needed for the design and 
conduct of long term carcinogenicity study and interpretation of the test 
results (Figure C) (Alden, 2000; Kim and Margolin, 1999). 
Principle of genotoxicity testing 
Chemicals that exert their adverse effects through interaction with the 
genetic material (DNA) of cells are called genotoxic (Brusick, 1987; 
Galloway, 1994). Most human carcinogens are gentoxic in nature (Jena, et 
al., 2002). The science of genotoxicity mainly concerns that, chemicals 
which induce mutations in various experimental models, may conceivably 
affect the incidence of heritable mutations in man (Davidson, et al., 1986; 
Douglass, ?^ ^/., 1988). 
Genotoxicity tests can be defined as in vitro or in vivo tests designed 
to detect drugs, which can induce genetic damage directly or indirectly by 
various mechanism of action. These tests enable hazard identification with 
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respect to DNA damage and its fixation in the form of genetic muatations, 
large-scale chromosomal damage, recombination and numerical 
chromosome changes. Drugs that are positive in these tests that detect such 
kind of damage have the potential to be human carcinogens and/ or 
mutagens i.e., may induce cancer and/ or heritable defects (Jena, et al., 
2002). Genotoxic studies along with data on pharmacokinetic (PK) and 
toxicokinetic (TK) represent a more rational approach for the assessment of 
mutagens and carcinogens (Frantz, et al., 1994). 
A large number of genotoxicity tests are presently available for use in 
hazard evaluation. These tests detect the tvs^ o main categories of mutations, 
gene mutation and chromosomal aberration, as well as indications of DNA 
damage. Tests to assess these endpoints can be carried out both in vitro and 
in vivo, with in vivo tests being conducted in germ cells, as well as in 
somatic cells. In order to assess adequately any expression of genotoxicity, a 
simplified systematic approach to the selection of these tests is required. 
Therefore, there must be an ordered approach using a limited number of 
well-defined tests that complement each other in terms of endpoints, and that 
permits a systematic assessment of genotoxicity. 
The standard test battery for genotoxicity 
For setting up of a battery of tests in genotoxicity assay, it has always 
been observed that, in vitro tests play a major role due to their high 
sensitivity and rapidity. Preliminary tests are designed in such a way that it 
can detect majority of the genotoxic carcinogens (MacGregor, et al, 1995). 
However, as no single assay has proved capable of detecting mammalian 
mutagens and carcinogens with an acceptable level of precision and 
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reproducibility, it is usual scientific practice to apply these assays in 
batteries. Initial information on the mutagenicity of a substance can be 
obtained using assays that measure gene mutations and chromosomal 
damage. Because separate procedures are required to investigate these end 
points, a battery of assays is needed. 
The general features of a standard test battery can be out lined as 
follows (Hutchinson, 2004): 
• It is appropriate to assess genotoxicity in a bacterial reverse mutation 
test. This test has been shown to detect relevant genetic changes and 
the majority of the genotoxic rodent carcinogens. 
• DNA damage considered to be relevant for mammalian cells and not 
adequately measured in bacteria should be evaluated in mammalian 
cells. Several mammalian cell systems are in use. These include 
systems that detect gross chromosomal damage (in vitro tests for 
structural and numerical chromosomal aberrations), systems that 
detect primarily gene mutations, and a system that detects gene 
mutations and clastogenic effects (mouse lymphoma tk assay). 
• An in vivo test for genetic damage should usually be a part of the test 
batter)' to provide a test model in which additional relevant factors 
(absorption, distribution metabolism, excretion) that may influence 
the genotoxic activity of a compound are included. As a result, in vivo 
tests permit the detection of some additional genotoxic agents. An in 
vivo test for chromosomal damage in rodent hematopoietic cells 
fulfills this need. This test could be either an analysis of chromosomal 
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aberrations in bone marrow cells or an analysis of micronuclei in bone 
marrow cells or peripheral blood erythrocytes. 
MUTAGENICITY TESTING STRATEGY 
A three level approach to genotoxicity testing based on the Level of 
Concern strategy in the report of the Environmental Contaminants Advisor} 
Committee on Mutagenesis has been adopted by the HPB. That Committee 
recommended the definition and use of "Levels of Concern" (LOC) to 
rationalize a systematic approach to testing (Environmental Health 
Directorate, Canada, 1993). 
Chemicals for which human exposure is high or widespread merit the 
greatest initial concern (LOC III), while those to which few people are 
exposed at very low dose levels would be of least concern (LOC 1). An 
intermediate level (LOC II) is also defined. Data from at least two different 
short-term in vitro tests would be standard for the toxicological evaluation of 
all chemicals for which human exposure is involved. Accordingly, 
substances assigned initially to LOC I should be subject to two short-term 
tests, one for gene mutations and the other for chromosomal aberrations in 
vitro. Chemicals initially assigned to the higher levels of concern (LOC II 
and III) should be subject to similar scrutiny, but additional data should be 
obtained initially for chromosomal aberrations in mammalian cells in vivo 
(Environmental Health Directorate, Canada, 1993) 
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SHORT TERM IN VITRO GENOTOXICITY ASSAYS USED TO 
DETERMINE GENOTOXICITY OF TEST CHEMICALS 
A. Chromosomal aberration assay 
Chemical causing chromosomal aberrations may be identified with an 
in vitro cytogenetic assay generally referred to as Chromosomal Aberration 
Test. The chromosome aberration test using cultured mammalian cells is one 
of the sensitive methods to predict environmental mutagens and/or 
carcinogens, and is a complementary test to the Salmonella/microsome assay 
(Ames test) (Ishidate, et al., 1998). The techniques used in the study of 
chromosomal aberration have been described in detail by Evans (1976) and 
in the Gene-Tox reports of Latt, et al. (1981) and Preston, et al. (1981). 
Human peripheral lymphocytes do not divide spontaneously in culture, but 
can be stimulated to divide by treatment with a mitogen such as 
phytohaemagglutinin (PHA). Cell cultures are treated with the test chemical 
and then mitosis is arrested in metaphase with an inhibitor, such as 
colchicine. The metaphase spreads are examined by light microscopy to 
detect chromosome or chromatid aberrations, or polyploid cells. A 
biologically significant increase in the frequency of cells with structural or 
numerical aberration compared with that of the concurrent control group 
indicates the chemical is clastogenic or aneugenic, respectively. Aberration 
types are usually classified into chromatid (involving only one chromatid) 
and chromosomal or isochromatid (affecting both chromatids) and are 
clearly described by Evans and O'Riordan (1975), Savage (1976), Basel and 
Karger (1978) and Scott, et al. (1983). Other classification systems have 
been devised, such as that of Buckton, et al. (1962), in which chromosome 
aberrations are classified as stable (Cs), such as translocations, or unstable 
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(Cu), such as dicentrics, depending on whether or not they can be maintained 
through successive cell cycles. Banding techniques (Evans, 1976). 
commonly used for detailed chromosome analysis, are rarely used for 
routine screening. 
B. Micronucleus assay 
The micronucleus assays are considered to be one of the preferred 
methods for assessing chromosome damage because they enable both 
chromosome loss and chromosome breakage to be measured reliably. This 
assay can provide, using simple morphological criteria, different measures of 
genotoxicity and cytotoxicity including chromosome breakage and loss 
(micronuclei), chromosome rearrangement (nucleoplasmic bridges), gene 
amplification (nuclear buds), cell division inhibition, necrosis and. 
apoptosis. This assay also has the added advantage that mitogenic response, 
a biomarker of immune responsiveness (Chandra, 2002) can be measured b> 
the proportion of cytokinesis-blocked BN and multinucleated cells or the 
estimated nuclear division index (Fenech, 2000). 
Micronulei (MNi) are expressed in dividing cells that either contain 
chromosome breaks lacking centromeres (acentric fragments) and/ or whole 
chromosomes that are unable to travel to the spindle poles during mitosis. At 
telophase, a nuclear envelope forms around the lagging chromosomes and 
fragments, which then uncoil and gradually assume the morphology of an 
interphase nucleus with the exception that they are smaller than the main 
nuclei in the cell, hence, they are called micronucleus (Fenech. 2000). 
Micronulei are expressed in cells that have completed nuclear division, and 
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thus, are ideally scored in the binucleated stage of cell cycle (Fenech and 
Morley, 1985). 
Occasionally nucleoplasmic bridges between nuclei in a binucleated 
cell are observed. These are probably dicentric chromosomes in which the 
two cetromeres are pulled to opposite poles of the cell and the DNA in the 
resulting bridge is covered by nuclear membrane. Thus, nucleoplasmic 
bridges in binucleated cells provide additional and complementary measure 
of chromosome rearrangement (Fenech, 2000). Some times binucleated cells 
also contain nuclear blebs or buds observed as outgrowths of main nucleus. 
These are the extruded amplified genes. 
The cytokinesis-block MN (CBMN) assay is the preferred method for 
measuring MNi in cultured human lymphocytes because scoring is 
specifically restricted to once-divided cells (Fenech, 2002; Fenech and 
Morley, 1986). In the CBMN assay, cells that have completed one nuclear 
division are blocked from performing cytokinesis using Cytochalasin -B (cyt 
-B). Cyt -B is an inhibitor of actin polymerization required for the formation 
of microfilament ring that constricts the cytoplasm between the daughter 
nuclei during cytokinesis (Carter, 1967). The CBMN assay is currently the 
most widely used method for measuring micronucleus frequency in human 
lymphocytes. The methods for performing the CBMN assay have been 
described recently (Fenech, 2000). 
C. Sister Chromatid Exchange assay 
Sister chromatid exchange (SCE) analysis in human peripheral blood 
lymphocytes has often been applied as a cytogenetic assay for biomonitoring 
and genotoxicity testing of potentially mutagenic and carcinogenic chemicals 
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(Natarajan, 2002). This assay is also termed as indicator test. Indicator tests 
are those that do not directly measure mutations, but rely on other markers. 
The mechanism of SCE formation was first proposed by Painter m 1980 
(Painter, 1980). 
The sister chromatid exchange (SCE) assay is a short-term test for the 
detection of reciprocal exchanges of DNA between two sister chromatids of 
a duplicating chromosome. SCEs represent the interchange of DNA 
replication products at apparently homologous loci. The exchange process 
presumably involves DNA breakage and reunion, although little is known 
about its molecular basis. Detection of SCEs requires some means of 
differentially labelling sister chromatids (Latt, 1974; Kato, 1974; and 
Korenberg and Freedlender, 1974) and this can be achieved by incorporation 
of bromodeoxyuridine (BrdU) into chromosomal DNA for two cell cvcles. 
SCEs can also be measured in mammals and in non-mammalian systems. 
Mammalian cells in vitro are exposed to the test chemical with and without a 
mammalian exogenous metabolic activation system, if appropriate, and 
cultured for two rounds of replication in BrdU containing medium. After 
treatment with a spindle inhibitor (e.g. colchicine) to accumulate cells in a 
metaphase-like stage of mitosis (C-metaphase), cells are harvested and 
chromosome preparations are made (Oecd, 1998). 
Because of the ease of preparation and scoring, it is a very widely-
used test in the study of mutagens. SCE induction alone is not generally 
accepted as sufficient evidence to classify an agent as mutagenic. The 
mechanism of SCE induction is not fully understood, though a number of 
models have been proposed (Wolff, 1982). Some clastogens induce only a 
small increase in SCEs, X-irradiation being a particularly striking example. 
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There is a high background level of SCE compared with chromosome 
aberrations; it is rare to find many cells without SCEs in untreated samples. 
This may be partly due to the 5-bromodeoxyuridine (BrdUrd) that is added 
to the culture medium in order to visualise SCEs, since BrdUrd itself is 
known to induce SCEs (Latt, et al., 1981). This basal level also implies that 
cells with SCEs are capable of subsequent growth. SCE evaluation may thus 
be a more valid indicator than chromosome breakage of events compatible 
with cell survival, hence its widespread use in mutagenicity screening 
programmes (IPCS, 1985). 
EVALUATION OF GENOTOXICITY IN PHARMACEUTICALS 
Pharmaceutical products are one of the fastest growing industries. 
Human aliments need the use of different drugs for the treatment of one or 
the other type of disease. Some diseases are chronic and require long-term 
treatment, thus exposing the human body to drugs and their byproducts for a 
longer duration of time. Many of these drugs cure health related problems on 
one hand, yet, on the other hand cause adverse side effects in human body, 
even affecting the human hereditary material, i.e. DNA at higher levels. 
HYPERTENSION 
Cardiovascular diseases (CVD) account for nearly a third of all deaths 
worldwide (WHO, 2002). CVD are increasing day by day in developing 
countries (Chockalingam and Balaguer-Vinto, 1999; Reddy and Yusuf, 
1998) and it has been estimated that CVD will be the major cause of 
morbidity and mortality in these countries by the year 2020 (Murray and 
Lopez, 1996). Consequently, the prevention of risk factors for CVD is a 
public health priority worldwide (WHO, 2002). 
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Hypertension is an extremely prevalent condition in industrialized 
countries, accounting for more than 5% of total deaths world wide (Schork, 
et al., 1999; Pardell, et al, 2000). About a quarter of the world's population 
have been estimated to have hypertension at the turn of the millennium 
(Kearney, et al., 2005). It has remained an important public health challenge 
in the developing and the developed world alike (Howson, 1998; Murray 
and Lopez 1996). 
A recent meta-analysis of the prevalence of HTN in India suggested 
that the prevalence of HTN is increasing steeply in urban areas (Gupta, 
1997). Hypertension is a silent killer. Indians are racially predisposed to 
cardiovascular disease and the increasing burden of hypertension has onl\ 
added to the problem. Economic constraints and the allure of additional 
benefits without adverse effects have made lifestyle modifications an 
attractive proposition in developing and developed countries alike. Blood 
pressure is a continuum and any increase above optimal level confers 
additional independent risk of vascular disease, even in ranges previously 
considered normal (Surya, et al., 2007). 
Hypertension (HTN), SBP (systolic blood pressure) >140 mmHg or 
DBP (diastolic blood pressure) >90 mmHg, is a premier risk factor for CVD. 
which is easily recognized if sought, and can be treated effectively. 
Treatment of high blood pressure (BP) has been consistently reported to 
reduce the risk of CVD (Staessen, et al, 2001). Control of HTN was defined 
as antihypertensive treatment associated with SBP and DBP less than 140 
mmHg and 90 mmHg, respectively (Guidelines Subcommittee, WHO, 
1999). 
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The duration of pharmacological treatment of hypertension may last 
for decades and, therefore, patients are exposed to prolonged contact with 
the drugs. Long - term treatments require documentation of long - term 
safety and efficacy including sensitive indices of genotoxic damage 
(Fmberg, et al., 1996) 
In prescribing a drug the knowledge of benefit / risk ratio is of 
fundamental importance. Among the various adverse reactions that a drug 
may cause, the possible occurrence of a carcinogenic effect can not be 
excluded. The development of a tumor may take place after more than 10 
and even 20 years of exposure (Giovanni and Antonietta, 2006). In the 2002 
edition of Martindale - The Complete Drug Reference there are 164 drugs 
used in the therapy of hypertension and the large majority of them are 
marketed in several countries. Along with many other drugs several 
antihypertensive agents belonging to different groups of this class of drugs 
were examined for the genotoxicity and carcinogenicity data and some of 
them were found to have all the genotoxicity and carcinogenicity data 
required by the ICH - harmonized guidance on genotoxicity testing of 
pharmaceuticals (Muller, et al., 1999; Snyder and Green, 2001; lARC. 
2004). 
CYTOGENOTOXIC EFFECTS OF CARDIOVASCULAR DRUGS -
AN INSIGHT 
Vasodilator and antihypertensive drugs are generally used for chronic 
long term therapy. Because of this long term drug exposure, scientific 
community has conducted several studies on many of such drugs. 
Genotoxic, cytotoxic and mutagenic potential of these drugs were evaluated 
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by measures like sister chromatid exchange (SCE) assay, chromosome 
aberration (CA) assay, cytokinesis-block micronucleus (CBMN) assay, 
bacterial mutation assay, comet assay etc. 
Hydrochlorothiazide, used as a diuretic and antihypertensive agent, 
was studied for its genotoxicity in cultured human lymphocytes. This drug 
produces micronuclei (MN) in cultured human lymphocytes by a mechanism 
that involves chromosome delay and to a lesser extent through chromosome 
breakage (Andrianopoulos, et al, 2006). 
Brambilla and Martelli (2006) collected data from 164 marketed 
antihypertensive drugs. Of these 48 drugs were found to have at least one 
positive finding. 32 drugs were tested positive in at least one genotoxicity 
assay, 26 in at least one carcinogenicity assay, and 10 in both at least one 
genotoxicity assay and at least one carcinogenicity assay. 
Genotoxic potential of chronic long - term therapy with the 
antihypertensive drug nimodipine was studied by measures of SCE and MN. 
A statistically significant increase in the frequency of micronuclei was 
detected in vitro (Telez, et ah, 2001) 
Cytogenotoxic effects of the vasodilator drug pentoxifylline, used for 
the treatment of peripheral vascular diseases and other related diseases, were 
investigated using cultured Chinese hamster V79 cells and human blood 
lymphocytes in vitro. The dose response clastogenicity was observed by 
measures of CA, SCE and MN formation (Bozsakyova, et al, 2001) 
Nitrovasodilators, represent a widely-used class of extremely effective 
itianginal medications capable of causing systemic and coronary-
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vasodilation whether or not the endothelium is intact. These agents lead to 
the formation of the reactive free radical nitric oxide (NO), hi vitro 
treatment indicated a dose-dependent increase in the frequency of 
micronucleated lymphocytes with increasing SNP concentrations. 
Cytotoxicity and cell cycle delay, with a statistically significant difference 
with respect to control culture, were also observed suggesting a possible 
genotoxic activity of nitrate therapy (Brambilla, and Martelli, 2006) 
A variety of cytogenetic effects of a )3- blocker antihypertensive drug 
Atenolol were observed in vitro. Chronic exposure to this drug led to a 
statistically significant enhancement of two variables of MN assay i.e. 
micronuclei and binucleated micronucleated cells (Telez, et al., 2000). 
Antihypertensive drugs hydralazine and dihydralazine can induce 
micronuclei in vitro, the effect depending on time exposure and 
concentration of the drugs (Chlopkiewicz, 1996). 
Methyldopa, a widely used antihypertensive drug, although has no 
clastogenic action, but causes a significant increase in SCE frequency in 
human lymphocytes in culture (Cesar and Catarina, 1991). 
Regarding the extensive use of various beta-adrenergic blockers for 
the treatment of a number of cardiovascular problems including cardiac 
arrhythmias, angina pectoris, and hypertension, eighteen beta-adrenergic 
blockers have been reviewed and the available literature pertaining to their 
potential carcinogenicity, mutagenicity, and teratogenicity has been 
summarized and compared (Jackson and Fishbein, 1986). 
35 
Besides cardiovascular drugs, metabolites of some vasodilator drugs 
like SIN -1 (3 - morpholinosydnonimine), the active metabolite of the 
vasodilator drug molsidomine, were found to produce a higher level of DNA 
double -stranded breaks in Tk6 cells and also induces mutagenesis and 
apoptosis in human lymphoblastoid cell lines (Li, et al., 2002) 
Although extensive work has yet not been done in the field related to 
cytogenotoxicity of cardiovascular drugs, in particular vasodilators and 
antihypertensives, and thus the above literature survey concerning 
cytogenotoxicity of these drugs is not very extensive, it indicates that many 
long- term therapy cardiovascular drugs have genotoxic potential that can 
not be neglected altogether. 
OBJECTIVES AND LIMITATIONS OF THE PRESENT WORK 
It is being increasingly recognized that high BP is an important public 
health problem in developing countries (Fuentes, et al., 2000). New research 
published in Lancet finds that India will bear 60% of the world's heart 
disease burden in the next two years (Xavier, et al., 2008; Eagle, 2008) In 
addition, researchers have determined that compared to people in other 
developed countries, the average age of patients with heart disease is lower 
among Indian people and Indians are more likely to have types of heart 
disease that lead to worse outcomes. 
Due to this threatening magnitude hypertension has received special 
attention during last decades. Treatment of hypertension along with other 
cardiovascular diseases requires long-term therapy involving the use of 
antihypertensive drugs. These drugs include diuretics, adrenergic beta-
antagonists, adrenergic alpha-antagonists, angiotensin-converting enzyme 
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inhibitors, calcium channel blockers, ganglionic blockers, and vasodilator 
agents. Vasodilator antihypertensives are generally used for cases of 
resistant or severe hypertension. 
The duration of pharmacological treatment of hypertension may last 
for decades and, therefore, patients are exposed to prolonged contact with 
these drugs. Long-term treatments require documentation of long-term 
safety and efficacy including sensitive indices of genotoxic damage 
(Furberg, etal., 1996). 
In order to assess whether chronic long-term cardiovascular drug 
therapy may produce chronic toxicological effects, four vasodilator 
antihypertensive drugs have been selected in the present study. 
The work has been conducted with a view to study the following 
objectives: 
1. To study the in vitro effects of the vasodilator antihypertensives 
through peripheral human lymphocyte culturing system. 
2. To study the genotoxic effects of the vasodilator antihypertensives on 
human chromosomes. 
3. The study of DNA damage caused by the vasodilator 
antihypertensives, at the chromosome level using cytokinesis-block 
micronucleus (CBMN) assay. 
4. To study the effects of vasodilator antihypertensives on cell/ nuclear 
division kinetics via cell cycle delay. 
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5. To study the cytotoxic effects (cellular cytotoxicity) of vasodilator 
antihypertensives on human peripheral lymphocytes. 
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MJATT^JICS & MTTMODS 
Chemicals can be tested for their ability to induce chromosomal 
damage either in mammals, cultured mammalian cells, insects or in plants. 
Mammalian cell cultures provide a convenient test system and either 
established cell lines or human blood lymphocytes can be used. Analysis of 
metaphase chromosomes in cells from the bone marrow of rats, mice, or 
hamsters is a well-established technique for studying chromosome damage 
in vivo. Alternatively, chromosome fragments can be identified as 
micronuclei in certain bone marrow cells and in other tissues and the 
"micronucleus test" has proved to be a relatively simple assay for detecting 
chemicals capable of damaging chromosomes. Cultures of mammalian cells 
can also be used to investigate the induction of gene mutations by chemicals 
in vitro. 
In the present investigation, four cardiovascular drugs were studied 
for the evaluation of genotoxicity in human peripheral blood lymphocytes in 
vitro. Blood donors were 20 - 35 years old healthy males and females. The 
genetic end points employed were widely used and readily available for 
evaluating somatic mutations in human beings. These end points were 
chromosomal aberrations (CA), micronuclei (MNi), binucleated 
mirconucleated (BNMN) cells, nucleoplasmic bridges (NPBR), nuclear buds 
(NBD) etc. and cell division kinetics. Statistical analysis was performed to 
ensure and find out significant values. 
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DESCRIPTION OF TEST DRUGS 
Four cardiovascular drugs were selected to assess their cytogenotoxic 
potential in human peripheral blood lymphocytes in vitro. Three of these 
drugs namely Pentoxifylline (Trental*), Isoxsuprine hydrochloride 
(Duvadilan*) and Xanthinol nicotinate (Complamina*) are vasodilators and 
one drug namely Metoprolol tartrate (Metolar*) is an antihypertensive. 
Together all of them are grouped as vasodilator antihypertensives. All these 
drugs were available in injections forms. 
1. PENTOXIFYLLINE / TRENTAL 
Pentoxifylline (PTX), a derivative of methylxanthine is an oxohexyl-
substituted analogue of theobromine. It was introduced originally for the 
treatment of peripheral vascular diseases, cerebrovascular disease and for a 
number of other disorders with defective micro- or macro-circulation 
Chemical nomenclature: 
Chemical formula of Pentoxifylline is (3, 7-dimethyl-l-[5-oxo-hexyl] 
xanthine) 
Chemical structure: 
Structural formula of Pentoxifylline is: 
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Indications: 
Nonhaemorrhagic stroke, chronic cerebrovascular insufficiency. 
transient ischaemic attack, intermittent claudication, trophic leg ulcers and 
gangrene, occlusive circulatory disturbances of the retina and cochlea, 
improves sperm motility. 
Contraindications: 
Hypersensitivity, acute myocardial infarction, retinal haemoirhage. 
2. ISOXSUPRINE HYDROCHLORIDE / DUVADILAN ' 
Isoxsuprine, or Isoxsuprine hydrochloride, is a beta agonist drug used 
as a vasodilator in humans and equines. It is a sympathomimetic agent \\'ith 
p-receptor stimulating effects, dilates blood vessels in skeletal muscle and 
stimulates the heart. Blood pressure is reported to be little affected but 
cardiac output increases; peripheral resistance falls while muscle blood flow 
increases. There is a relaxation of the uterine muscles (Goodman and 
Oilman, 1965). 
Chemical nomenclature: 
Chemical formula of Isoxsuprine hydrochloride is 2-hydroxy-2-(4-
methoxyphenyl)-l-methyl-N-(l-phenoxy- 2-propyl) ethanaminium chloride. 
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Chemical Structure: 
Structural formula of Isoxsuprine hydrochloride is: 
CH-) CH'< 
I H I H 
OH k -jJ 
Indications: 
Peripheral vascular disorder, intermittent claudication, Buerger's 
disease, night legcramps, premature labour, habitual abortion, threatened 
abortion, cerebral vascular disease. 
Contraindications: 
Recent haemorrhage, severe anemia,premature detachment of 
placenta, immediate postpartum,parenteral use in patient with known heart 
disease. 
3. XANTHINOL NICOTINATE / COMPLAMINA " 
Xanthinol nicotinate is a peripheral vasodilator (nictonic acid 
prodrug). It is the most potent form of niacin (active part of vitamin B3j, 
stimulates memory and concentration by improving the brain's blood flow. 
It passes easily through cell membranes. 
Xanthinol Nicotinate has been shown to increase brain glucose 
metabolism, improve brain ATP levels and improve brain blood flow (it acts 
as a vasodilator). As such, Xanthinol Nicotinate has been used to treat short-
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term memory disorders, mental flagging (i.e., lack of brain energy that 
compromises vigilance, concentration and attention) and insufficient blood 
flow to the arteries and the extremities. Furthermore, Xanthinol Nicotinate 
has been clinically shown to improve the reaction speed of the elderly. 
Chemical nomenclature: 
Chemical formula of xanthinol nicotinate is 7-[2-Hydroxy-3-(2-
hydroxyethyl-methyl-amino) propyl]-1, 3-dimethyl-purine-2, 6-dione 
pyridine-3-carboxylic acid 
Chemical Structure: 
Structural formula of xanthinol nicotinate (C13H21N5O4 • C6H5N02)is: 
0 
CH, 
Oh CH, 
CH2CHCH2NCH2CH2QH 
O ' -<' N N' 
I 
CH, 
^y ^ / 
0 
II 
C - O H 
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Indications: 
Peripheral vascular disease, disordered cerebral function, 
hyperlipidaemia. 
Contraindications: 
Hypersensitivity towards the product, cardiac decompensation, acute 
hemorrhaging, cerebral infarction, acute myocardial infarction (this product 
is not recommended in the case of coronary insufficiency due to the danger 
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of myocardial infarction), vascular collapse, association with MAO inhibitor 
or ganglioplegic treatment, gastroduadenal ulcer in it's evolutionary phase. 
4. METOPROLOL TARTRATE / METOLAR ' 
Metoprolol tartrate is an antihypertensive drug. It is a selective betal-
adrenoreceptor blocking agent. The in vitro and in vivo animal studies have 
shown that it has a preferential effect on beta! adrenoreceptors, chiefly 
located in cardiac muscle. This preferential effect is not absolute, however, 
and at higher doses, metoprolol also inhibits beta2 adrenoreceptors. chiefly 
located in the bronchial and vascular musculature. The tartrate is used in 
both oral and intravenous formulations. 
Chemical nomenclature: 
Chemical formula of Metoprolol tartrate is l-Isopropyiamino-3-[4- (2-
methoxyethyl) phenoxy]-2-propanol L-(+)-tartrate 
Chemical Structure: 
Structural formula of Metoprolol tartrate is: 
" • \ \ ^ " ^ 
Indications: 
Used alone or in combination with other antihypertensive agents, for 
management of hypertension, long-term management of angina pectoris, 
myocardial infarction (immediate-release tablets and injection). 
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Contraindications: 
Greater than first-degree heart block, congestive heart failure unless 
secondary to tachyarrhythmia treatable with beta-blockers, overt or moderate 
to severe cardiac failure, sinus bradycardia, cardiogenic shock, 
hypersensitivity to beta-blockers, systolic blood pressure < 100 mm/Hg, Ml 
in patients with heart rate < 45 beats/min. 
DESCRIPTION OF CONTROL CHEMICALS 
I. Negative control (Dimethyl sulphoxide, DMSO) 
In the present investigation the test drugs used are in injection form. 
So the solvent control used is the organic compound Dimeth> 1 sulphoxide 
(DMSO), which is being successfully employed as solvent for most of the 
formulations. It has been reported to be non - toxic to animals and humans 
(Preston, et al., 1987). This negative control provides the baseline to which 
the data were compared to see the significant effects. 
CH^ 
CH5 
' \ « = o 
/ 
2. Positive control (Cyclophosphamide, CP) 
Cyclophosphamide (endoxan) is the most versatile therapeutic drug 
which possess the broadest spectrum and antitumor activity of all alkylating 
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agents (Brock, 1967). It has strong mutagenic effects. It acts by forming 
DNA crosslinks by the reaction of chloroethyl moieties of CP with adjacent 
nucleotide bases. This drug is widely used as positive control in in viti 
assays. 
"O 
MATERIALS 
L Chemicals and biochemicals 
Glacial acetic acid 
Methanol 
Potassium chloride 
Potassium dihydrogen phosphate 
Sodium bicarbonate 
di-Sodium hydrogen phosphate 
Qualigens (GSK Pharmaceuticals) 
Qualigens (GSK Phannaceuticals) 
Qualigens (GSK Pharmaceuticals) 
Qualigens (GSK Pharmaceuticals) 
SD Fine (SD Fine Chemicals) 
Qualigens (GSK Pharmaceuticals) 
2. Test drugs and solvent controls 
Pentoxifylline 
Isoxsuprine hydrochloride 
Xanthinol nicotinate 
Metprolol tartrate 
Dimethyl sulphoxide (- control) 
Cyclophosphamide (+ control) 
Aventis (Aventis Pharma) 
Solvay (Solvay pharma) 
Cadila Healthcare 
Cipla (Cipla, India) 
Qualigens (GSK Pharmaceuticals) 
Qualigens (GSK Pharmaceuticals) 
3. Solutions and buffers 
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Cell culture (CA assay and CBMN assay) 
Antibiotic Antimycotic solution 
Colchicine 
Cytochalasin - B 
Fetal calf serum (FCS) 
"^ ""Heparin Sodium (Beparin) 
Phytohaemagglutinin (PHA-M) 
RPMI Medium 1640, 
(with L - glutamine) 
Gibco ^^ (Invitrogen Corporation) 
Loba Chemie 
Gibco (Invitrogen Corporation) 
Sigma - Aldrich 
BE (Biological E.) 
Gibco BRL (Life Technologies) 
Gibco ^^ (Invitrogen Corporation) 
Stainins 
Giemsas stain solution 
Sorensen's buffer 
• KH2PO4(0.1M) 
• Na2HPO4(0.1 M) 
Merck 
4. Software 
Microsoft Office 2007 
SPSS 11.0 for Windows 
Curve Expert 1.3 
METHODS 
1. In vitro testing of chromosomal aberrations (CA assay) 
A. Cell cultures: 
a. Preparation of stock culture media 
Culture media from RPMI 1640 with L - glutamine was prepared b} 
dissolving the powdered media (x g) in 1 liter {1000 ml) double distilled 
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autoclaved water by gentle shaking. pH was adjusted at 7.4 with 2 g 
NaHCOs. Then 10 ml of antibiotic - antimycotic (10,000 units /ml penicillin 
G sodium, 10,000 |ig /ml streptomycin sulphate and 25 |ig /ml amphotericin 
B) was also added. Contents were mixed gently and thoroughly and the 
media was then filter sterilized in the negative pressure Millipore filtration 
assembly by using 0.22 ^M millipore filters. This IX filtered stock medium 
was then stored in sterilized and tightly capped bottles at 4° C in dark. 
b. Preparation of working media 
The working medium was prepared from above stored stock medium 
under the sterile conditions of laminar flow. For the preparation of 100 ml 
working medium, 79 ml (IX) stock medium, 20 ml fetal calf serum 
(supplement) and Iml of heparin (anticoagulant) were mixed respectively 
and then pH of the solution was checked to 7.4 using pH strips under the 
range. 
c. Collection of blood samples 
5 ml peripheral blood from healthy donors was collected by 
venipuncture under aseptic conditions using sterile disposable syringes 
(Dispovan*) of 5 ml capacity. Heparin (500 lU / ml; Biological E.) was used 
as anticoagulant. Blood was stored in sterile collection vial at 4° C for half 
an hour to separate red blood cells (RBC, s) from plasma. Fresh collection 
was done every time before each experiment. 
d Setting of the cultures 
Culture was set according to the standard techniques of Moorhead, et 
al. (1960) and Evans, (1976) with few lab modifications under the sterile 
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conditions of laminar flow hood. 4.5 ml of working medium was taken in 10 
- 15 ml capacity sterile culture glass vial and 0.1 ml phytohaemagglutinin -
M (PHA - M), a mitogen, was added to it. Lymphocyte culturing was done 
by adding 0.8 ml of plasma containing white blood cells (WBC,s) in the this 
medium and the contents were mixed gently. The culture vials were then 
tightly capped and sealed with parafilm to avoid CO2 loss and culture was 
incubated at 37° C in dark for 72 hours. 
e. Chemical exposure 
Human peripheral lymphocytes were incubated for 48 hours at 37°C 
before the test drugs were added to culture medium. After cultivation for 
further IVA hours, i.e. IV2 hours prior to harvesting. Colchicine (0.20 jiig/ 
ml) was added to arrest the cells at metaphase stage. 
Drug concentrations were selected as per previous work on this class 
of drugs (Bozsakyova, et al., 2001) on the basis of preliminary cytotoxicity 
tests. The highest concentration of the drug suppressed the mitotic activity of 
the cells by nearly 50%. 
For control cultures, Dimethyl sulphoxide (negative control) and 
Cyclophosphamide (positive control) were added to cultures. 
/ Harvesting of culture 
After 72 hours the cultures were taken out of 37° C incubator 
temperature and the contents were mixed and transferred to the 15 ml 
centriftige tubes for centrifiigation. The cells were then spun down by 
centriftigation (10 minutes, 1000 rpm) and the pellet was saved. 
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Hypotonic treatment (0.53 % KCl) was done for about 20 minutes at 
37° C. Pellet was again saved by centrifugation (10 minutes, 1000 rpm). 
Saved pellet was then fixed with 5 ml chilled fixative (1:3 acetometanol). 
Cells were washed 2 -3 times with fixative before white pellet was obtained. 
For proper fixation, cells were kept for 1 hour and preferably overnight at 4° 
C. 
B. Slide preparation and staining 
Fixed cells were resuspended in 0.2 ml fresh fixative. Two or three 
drops of suspended cells were dropped on clean, grease free, pre-chilled wet 
microscope slides of super deluxe quality. These slides were then air dried 
and left for over night before staining and storage. 
One - day old slides were stained in 5% Giemsa's stain in Sorensen"s 
buffer (pH 6.8) for 10 - 15 minutes and then rinsed in distilled water to 
avoid excess stain before drying. 
C. Analysis of the cells 
All slides were first marked accordingly. Nearly 100 to 300 
metaphases were analyzed for each concentration of test drug. Chromosomal 
aberrations were scored as chromatid, isochromatid and exchanges as per the 
classification of Evans (1984) and Savage (1976). Percent aberrant 
metaphases were also scored. 
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2. In vitro Cytokinesis - Blocked Micronucleus (CBMN) assay 
A. Setting of the culture and harvesting 
CBMN assay was carried out as per standard technique of Michael 
Fenech (2000) with some lab modifications. In this assay, the initial steps 
employed in setting the culture were the same as in CA assay, except the test 
drug exposure time and addition of Cytochalasin - B (a microfilament-
assembly inhibitor) to culture medium. 
In CBMN assay, human peripheral lymphocytes were incubated for 
24 hours before the test drugs were added to culture medium containing 20 
% FCS and 0.\ ml PHA - M. Cultures were further incubated at 3TC for 20 
hours and Cytochalasin - B ( 3^g cyt - B / ml) was added to each culture at 
44 hour after PHA stimulation. 
After 28 hours of adding C>'t - B, cells were harvested b\' 
centrifugation. Hypotonic treatment (prewarmed 0.53 % KCl) was given for 
a very short period of 1 - 2 minutes, followed by cell fixation in fresh and 
chilled acetomethanol solution (1:3). 
B. Slide preparation and Staining 
Slides were prepared by dropping 2 drops of fixed solution over clean 
and chilled wet glass slides. They were then air dried and left for one day. 
One - day old slides were stained in 5% giemsa solution in 50 ml of 
Sorensen's buffer (pH 6.8) for 15 - 20 minutes. 
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C. Analysis of cells 
Stained slides were marked accordingly and observed under 100 X 
lens of light microscope (Olympus-13X50,Japan) with camera attachment 
(ProgrRes® C3,Jenoptik, Germany) and a monitor to observe and capture 
cellular details. About 1000 binucleated cells were scored for micronucleus 
estimation, nucleoplasmic bridges, nuclear buds and binucleated 
mirconucleated cells. About 500 cells were observed for other measures like 
mono -, bi -, tri - and tetranucleate cells, and apoptotic and necrotic cells 
(Fenech, 2000) 
3. Cell division kinetics 
In CBMN assay, the cells with one (Ml), two (M2), three (M3) and 
four (M4) nuclei were scored from a population of 500 viable cells, and 
apoptotic (nuclear fragmentation with intact cytoplasm) and necrotic cells 
(vacuolated pale cytoplasm with damaged membrane and intact nucleus or 
loss of cytoplasm with damaged membrane and partially intact nucleus) 
along with cells with 1 - 4 nuclei were detected in 500 viable and non -
viable cells. Nuclear division index (NDI) was calculated as per the method 
given by Eastmond and Tucker (1989) using the formula: 
NDI = [Ml +2(M2) + 3(M3) + 4(M4)J /N 
Where Ml - M4 represented the number of cells with one to four nuclei and 
N was the total number of viable cells. The NDI and the proportion of 
binucleated cells were used as useful parameters for comparing the 
mitogenic response of lymphocytes and cytostatic effects of drugs examined 
in this assay. 
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More accurate assessment of nuclear division status and cell division 
kinetics was obtained by including necrotic and apoptotic cells in the study. 
This inclusion resulted in attainment of nuclear division cytotoxicity index 
(NDCI) using the equation: 
NDCI = (Ap + Nee + Ml + (M2) + 3(M3) + 4(M4)] /N* 
Where Ap = number of apoptotic cells, Nee - number of necrotic cells, Ml 
- M4 = number of viable cells with 1 -4 nuclei and N*= total number of 
cells scored (viable and non - viable). 
The deviation from the control was determined by using Chi - square 
test for above parameters. 
4. Statistical evaluation of the test results 
Statistical packages (Microsoft Office excel 2007, SPSS 11.0 for 
Windows and Minitab 15 English) and statistical calculator were used to 
analyze results. Mean, Standard Deviation (SD) and Standard Error of Mean 
(SEM) were calculated first. The standard error for individual observations 
and for control reading was calculated using the formula 
SE = V [(1-n) n / N] 
Where n indicates individual reading and N is taken as 100 (for 100 cells of 
study). 
Student's two tailed't' test was used for calculating the statistical 
difference in chromosomal aberrations and MNT (micronucleus test) 
variables (micronuclei, binucleated mirconucleated cells, nucleoplasmic 
bridges, nuclear buds etc), by comparing the effects induced by different test 
53 
drugs with that of respective controls. The statistical significance was 
calculated from Fisher and Yates table at (ni+n2-2) degree of freedom at 
0.005% level of significance (p). 
2x3 Chi-Square test (x ") for homogeneity of variance was used to 
analyze cell division kinetics of test drugs compared with the control values. 
The level of significance was tested from standard statistical tables of Fisher 
and Yates (1963) at P < 0.005%. 
In case of chromosomal alterations conditions like endoreduplication, 
ploidies, pulverizations and cells with multiple anomalies were not included 
in the statistical analysis due to their very few numbers. 
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%TStL£TS 
%Tsv.Lrs 
In the present study, four commonly recommended cardiovascular 
drugs, i.e., Pentoxifylline (TrentaP), Isoxsuprine hydrochloride 
(Duvadilan*), Xanthinol nicotinate (Complamina*) and Metoproiol tartrate 
(Metolar*) were assessed for their genotoxic potential in vitro. The 
genotoxic potentiality was checked at five different concentrations of drugs 
and the time of exposure was kept constant for each concentration. Two 
short-term but high potential assays, namely Chromosomal aberration assay 
and C>tochalasin-block micronucleus assay, were employed to test drug 
genotoxicity and cytotoxicity. Six parameters were applied to evaluate the 
results. For statistical analysis, Student's r-test was used for the comparison 
of chromosomal aberrations, binucleated mirconucleated cell frequencies, 
micronucleus frequencies, nucleoplasmic bridge frequencies and nuclear bud 
frequencies of test drugs with that of controls. The 2x3 Chi-Square (x ) test 
was used for nuclear/cell division kinetics and nuclear division cytotoxicity 
index studies of test drugs and results were compared with controls. The 
level of significance was studied at P < 0.005 for both the parametric tests. 
Comparative analysis of the four tested drugs was also done as part of 
the present study. The drugs were studied for their relative responses to the 
above used parameters in order to check out the highest response and the 
lowest one. 
1. PENTOXIFYLLINE (TRENTAL") 
(a) Chromosomal aberrations: 
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The results of chromosomal aberrations analyzed for five different 
concentrations (0.15 mg/ml, 0.30 mg/ml, 0.60 mg/ml, 1.00 mg/ml and 2.00 
mg/ml) Pentoxifylline at 48 hour of incubation are summed up in Table 1. 
As given in the table, the percentage of aberrant metaphases has increased 
gradually (40, 53.3, 54.5, 53.3 to 68.7) with the increasing concentrations of 
the drug except for one value at 0.6 mg/ml concentration, where the 
percentage of aberrant metaphases has dropped slightly. Aberrations per cell 
also showed the same pattern of increased values against increasing drug 
concentrations respectively. Statistically analyzed by applying Student's /-
test, all these values were highly significant at P < 0.005, compared to the 
negative control value. The results of the positive control were also 
significant at P < 0.005 at 48 hour of incubation. 
The higher frequencies of aberrant metaphases have also been 
depicted in bar graph where the increasing bar lengths, indicative of the 
aberrant metaphase frequencies, was observed with increasing 
concentrations of the drug (Fig. 1). 
Regression analysis of aberrations per cell revealed dose-response 
curve plotted for increasing drug concentration versus increasing aberrations 
per cell. A positive correlation was found between above two variables 
(Correlation coefficient R = 0.35). The best fit regression line determined by 
least squares method along with line equation is shown in Fig. 2. 
(b) Micronucleus and Binucleated mirconucleated cell frequencies 
The results of the CBMN assay for Micronucleus (MN) frequencies 
and Binucleated Mirconucleated (BNMN) cell frequencies are depicted in 
table 2 and table 3 respectively. Table 2 shows that MN induction has 
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increased with the respective drug concentration. Statistically speaking, the 
last four values (5.1%, 5.6%, 6.7% and 15.0%, at concentrations of 0.30 
mg/ml, 0.60 mg/ml, 1.00 mg/ml and 2.00 mg/ml respectively) were 
significantly different with respect to control values at (P < 0.005) (Student's 
r - test), while at initial drug concentration of 0.15 mg/ml, the difference was 
insignificant. 
The observed frequencies of BNMN cells also increased gradually for 
the increasing drug concentrations as percent values 2.8, 5.1, 5.6, 6.7 to 10.0. 
This increase was in line with the increase of MN frequencies, the only 
difference being that at the highest dose i.e., 2.00 mg/ml, MN frequency is 
slightly higher (15.0%)) as compared to the frequency of BNMN cells 
(10.0%) of the same concentration. Considering the statistical analysis of 
BNMN cell frequencies, similar results were obtained as in the case of MN 
induction. Here the last four values were also found to be highly significant 
at P < 0.005, as compared to control value for 24 hour of incubation, the first 
value was insignificant at P < 0.005. 
Regression analysis of micronucleus frequencies plotted against drug 
concentrations reveals dose-response curve. The observed MN frequencies 
correlated highly and positively (Correlation coefficient R = 0.97) with drug 
concentrations applied. The best fit regression line (determined by least 
squares method) and the regression line equation describing it are presented 
in Fig. 3. 
Bar graph analysis of BNMN cell frequencies (minus negative 
control) drawn against drug concentrations also revealed increased bar 
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lengths (increased BNMN cell frequencies) with increasing concentrations 
of the respective drug (Fig. 4). 
(c) Nucleoplasmic bridge frequencies: 
Table 3 indicates the results of nucleoplasmic bridge (NPB) 
frequencies induced by the drug pentoxifylline. This table shows relative 
occurrence of nucleoplasmic bridges in 1000 binucleated cells. Frequencies 
of NPB, s, although did not show consistent increase with increasing drug 
doses, but an over all increase in the effect was seen comparing lowest drug 
dose (0.15 mg/ml), and highest drug dose (2.00 mg/ml) respectively. At 
0.15 mg/ml concentration, the NPB frequency was 12.9 % while at 2.00 
mg/ml concentration the NPB frequency was increased to 28.6 %. This 
result is highly significant at P < 0.005 as compared with the control. 
The dose-depended nucleoplasmic bridge frequencies were also 
shown in Fig. 4, where increased bar lengths were observed with increasing 
drug doses (0.15 mg/ml, 0.30 mg/ml, 0.60 mg/ml, 1.00 mg/ml and 2.00 
mg/ml respectively) indicating increased NPB frequencies. 
(d) Nuclear bud frequencies: 
The results of nuclear bud (NB) frequencies are also shown in table 3. 
These frequencies were low as compared to other parameters shown in the 
same table i.e. micronuclei and nucleoplasmic bridges. The observed range 
varied in percentage from 2.6, 3.0, 4.0, 6.6 to 9.0, indicating that the effect 
got increased with increasing respective drug concentrations (0.15 mg/ml, 
0.30 mg/ml, 0.60 mg/ml, 1.00 mg/ml and 2.00 mg/ml). The initial two 
values, at drug concentrations of 0.15 mg/ml and 0.30 mg/ml respectively, 
58 
were not significant at P <0.005 level. The value at 0.60 mg/ml 
concentration was observed to be significant, while for the last two final 
concentrations, i.e., 1.00 mg/ml and 2.00 mg/ml respectively, the results 
were highly significant compared to the control (P < 0.005). 
Graphical presentation of NB frequencies drawn against drug doses 
showed the increased bar length pattern (NB frequencies), with increasing 
drug concentrations (Fig. 4). 
(e) Nuclear Division Index (Cell Division Kinetics): 
The extent and progression of nuclear division could be assessed by 
analyzing the nuclear division index (NDI). The data for nuclear/cell 
division kinetics of the drug Pentoxifylline is presented in Table 4. This 
table also contains viable (mononucleated, binucleated, trinucleated and 
tetranucleated) cell values. The NDI was 1.25 at lowest drug concentration 
of 0.15 mg/ml, while at highest concentration of 2.00 mg/ml, the NDI value 
was 1.06. Other NDI values fell in middle range as 1.10, 1.03 and 1.07 at 
drug doses of 0.30 mg/ml, 0.60 mg/ml and 1.00 mg/ml respectively. All 
these values were highly significant at P < 0.005, when compared to control 
which has an NDI value of 1.24. The calculation of the NDI revealed that 
there was a significant cell cycle delay detectable after exposing culture cells 
for 24 h to drug with increasing concentrations (0.15 mg/ml, 0.30 mg/ml, 
0.60 mg/ml, 1.00 mg/ml and 2.00 mg/ml). 
Regression analysis of the parameter NDI showed statistically 
significant (P< 0.005) negative correlafion between the two variables, i.e. the 
drug concentrafions versus NDI (Correlation coefficient R = 0.54). The best 
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fit regression line determined by least squares method along with 
regression line equation is presented in Fig. 5. 
(a) Nuclear Division Cytotoxicity Index (NDCI): 
Table 5 reveals nuclear division cytotoxicity index (NDCI) for the 
drug Pentoxifylline. In this table mononucleated, binucleated, trinucleated, 
tetranucleated, apoptotic and necrotic cells were also scored. It is apparent 
from the table that the NDCI values decreased over all, as the drug doses got 
increased (1.20 at lowest concentration and 1.05 at highest concentration), 
thus indicating the cytotoxic effects and cell cycle delay which are 
indicatedby a reduction in the NDCI values. The only exceptions were for 
0.60 mg/ml and 1.00 mg/ml drug concentrations, where the values showed a 
gradual increase. The obtained range for NDCI values was 1.20. 1.10. 1.02. 
1.05 and 1.05 respectively. Statistical analysis of the data, applying ^ ; test. 
showed that all values were highly significant at P< 0.005 compared with 
the control value (1.192). 
Study of the best fit regression line showed a negative correlation 
between drug concentrations and NDCI values for Pentoxifylline 
(Correlation coefficient R = 0.56) (Fig. 6). 
1. ISOXSUPRINE HYDROCHLORIDE (DUVADILAN*) 
(a) Chromosomal aberrations: 
Table 6 represents the results of chromosomal aberrations studied at 
five different concentrations (0.15 mg/ml, 0.30 mg/ml, 0.60 mg/ml, 1.00 
mg/ml and 2.00 mg/ml) of the drug Isoxsuprine hydrochloride at 48 hour of 
incubation. According to the table, percentage of aberrant metaphases 
68 
increased gradually with the increasing concentrations of the drug. However, 
two of the values (at 0.30 mg/ml and 2.00 mg/ml drug respectively), showed 
contrasting results. Thus, to summarize the effect, 46.15 % abnormal 
metaphases were found at 0.15 mg/ml drug concentration, while this 
percentage got increased to 71.4% at 2.00 mg/ml of drug concentration. 
Statistically, all values were highly significant at P < 0.005 when compared 
with negative control. The positive control also showed significant effect at 
P < 0.005 for 48 hour of incubation. Similarly, the study of aberrations per 
cell showed an over all increased effect of the drug, the values being 0.39, 
0.61, 0.93, 1.01 and 1.00 at 0.15mg/ml, 0.30 mg/ml, 0.60 mg/ml, 1.00 
mg/ml and 2.00 mg/ml of drug concentrations respectiveh. Ail these 
readings along with the positive control reading were highly significant at P 
< 0.005. 
Graphical presentation of aberrant metaphases per 100 normal 
metaphases (minus negative control) displayed the high frequency with 
increased drug concentrations, except for the two contrasting values (Fig. 7). 
Regression analysis of aberrations per cell between increased drug 
concentration and increased aberrations per cell showed a positive 
relationship, (Correlation coefficient R = 0.76). The best fit regression line 
determined by least squares method and the equation of the line are shown in 
Fig. 8. 
(b) Micronucleus and Binucleated mirconucleated cell frequencies 
Table 7 and table 8 summarize the results of the CBMN assay for 
Micronucleus (MN) and Binucleated Mirconucleated (BNMN) cell 
frequencies respectively. As per Table 7, drug Isoxsuprine hydrochloride 
69 
induced MN frequencies displayed an increased pattern with increased drug 
concentrations respectively, except for one reading at 0.60 mg/ml drug dose 
showing a much lesser value than others. The range of the frequencies of 
MNi in percentage was from 2.0, 10.0, 2.8, 13.3 to 14.3 respectively. 
Statistically speaking, two values (at 0.15 mg/ml and 0.60 mg/ml drug 
concentrations) were not significant, while rest of the three values were 
highly significant at P < 0.005. 
The observed frequency of BNMN cells increased gradually from 2.0. 
6.0, 2.8, 13.3 and 14.3 in percent, with increasing drug concentrations 
(0.15mg/ml, 0.30 mg/ml, .60 mg/ml, Img/ml and 2mg/ml) excepting one 
value at 0.60 mg/ml drug dose. The values at 0.30 mg/ml. 1 mg/ml and 
2mg/ml were found to be highly significant statistically at P < 0.005. 
compared to negative control value at 24 hour of incubation. Rest two values 
were not significant at P < 0.005, level. 
Regression graph analysis of MN frequencies plotted against drug 
concentrations (minus control) revealed dose - response curve indicating 
increased MN induction with increasing drug doses. Correlation between the 
two parameters was positive with Correlation Coefficient, R being 0.73. The 
best fit regression line obtained by least squares method and regression line 
equation were shown in Fig. 9. 
The bar diagram analysis of BNMN cell frequencies (minus control) 
drawn against drug concentrations also showed increased bar lengths 
(symbolizing BNMN cell fi-equencies) with increasing drug doses 
respectively (Fig. 10). 
(c) Nucleoplasmic bridge frequencies: 
70 
The results of nucleoplasmic bridge (NPB) frequencies for the dmg 
Isoxsuprine hydrochloride are presented in Table 8. This table shows relative 
occurrence of nucleoplasmic bridges in 1000 binucleated cells. NPB 
frequencies increased consistently with drug doses, but at one concentration 
(0.30 mg/ml), a contrasting value was obtained. However an over all 
increase in the effect was obtained comparing the lowest drug dose (0.15 
mg/ml) and highest drug dose (2.00 mg/ml) respectively. At 0.15 mg/ml 
concentration the NPB frequency was 14.3 % while at 2.00 mg/ml 
concentration, the NPB frequency got increased to 28.6 % for the drug 
Isoxsuprine hydrochloride. Statistically, all the values were highly 
significant at P < 0.05 as compared with the negative control. 
NPB frequencies plotted against drug concentrations showed a dose-
dependant graph indicating elevated response shown by bars (Fig. 10). 
(d) Nuclear bud frequencies: 
Table 8 also summarizes the results of nuclear bud (NB) frequencies, 
for the drug Isoxsuprine hydrochloride. The observed range was 5.3%, 8.3%. 
7.1 %, 6.3 % and 10.0 % at drug concentrations 0.15 mg/ml, 0.30 mg/ml. 
0.60 mg/ml, 1.00 mg/ml and 2.00mg/ml respectively. According to the 
obtained series, the effect did not increase uniformly, however considering 
the lowest drug concentration and the highest drug concentrations, the 
increased response was obtained. Analyzing statistically, all the values were 
highly significant as compared with the negative control value at P < 0.005. 
The bar diagram drawn for NB frequencies against drug doses also 
indicated the same result (Fig. 10). Here increased bar length pattern were 
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obtained with increased drug concentrations respectively. Control reading 
was not plotted in the graph. 
(e) Nuclear Division Index (Cell Division Kinetics) : 
The data for nuclear/cell division kinetics of the drug Isoxsuprine 
hydrochloride is shown in Table 9. Cells with one, two, three and four nuclei 
were also scored in the table. Cell division kinetics involving nuclear 
division is studied through nuclear division index (NDI). According to the 
table, the NDI value reduced down for lowest drug concentration (0.15 
mg/ml) to the highest drug concentration (2.00 mg/ml) gradually. The 
observed pattern of reduction in NDI values was 1.24, 1.21, 1.21. 1.22, and 
1.16 respectively indicating a significant cell cycle delay due to drug 
exposure. Statistical analysis, applying 2X3 Chi-square test, indicated that 
these values were highly significant at P < 0.005 when compared with the 
control which has an NDI value of 1.24. 
A negative correlation was observed between the two measures, i.e.. 
drug concentrations and NDI (correlation coefficient, R = 0.88). Regression 
graph analysis of the parameter NDI showed a best fit regression line 
determined by least squares method. The regression line and equation are 
presented in Fig. 10. 
(f) Nuclear Division Cytotoxicity Index (NDCI): 
A more accurate assessment of nuclear division status along with 
nuclear cytotoxicity measure can be obtained through Nuclear Division 
Cytotoxicity Index (NDCI). NDCI for Isoxsuprine hydrochloride is given in 
Table 10. Besides mononucleated, binucleated, trinucleated and 
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Fig. 9. Dose-response curve of micronuclei frequencies in human 
lymphocytes in vitro treated with different concentrations of 
Isoxsuprine HCl. 
La;ver\', 
BNNB Fr«qu«fKi«i (%) 
BNNPB Frequencin (%) 
BNMN <r«qtMrKi«» (%) 
Drug concentrations (mg/ml) 
Fig. 10. Frequencies of binucleated micronucleated cells, nucleoplasmic 
bridges and nuclear buds in human lymphocytes in vitro plotted 
against different concentrations of Isoxsuprine HCl. 
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Fig. 11. Dose-response curve of nuclear division indices in human 
lymphocytes in vitro treated with different concentrations of 
Isoxsuprine HCl. 
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Fig. 12. Dose-response curve of nuclear division cytotoxicity indices in 
human lymphocytes in vitro treated with different 
concentrations of Isoxsuprine HCl. 
tetranucleated cells, apoptotic and necrotic cells are also included in 
the table. Study of the table revealed that the NDCI values decreased (1.20. 
1.18, 1.18, 1.17 and 1.17) as the drug doses increased gradually (from 0.15 
mg per ml to 0.30, 0.60, 1.00 and 2.00). The gradual decrease in NDI range 
was indicative of cellular toxicity of drug in vitro at the concentrations 
tested. Statistical examination of the data, applying % ^ test, shows that all 
values are highly significant at P< 0.005, compared with the control value 
(1.192) except for a single one which is not significant at lowest drug dose. 
Regression line analysis showed a highly strong negative correlation 
between drug concentrations and NDCI for Isoxsuprine hydrochloride 
(correlation coefficient, R = 0.97). The best fit regression line along with the 
equation of the line is shown in Fig. 12. 
3. XANTHINOL NICOTINATE 
(a) Chromosomal aberrations: 
Data for the analysis of chromosomal aberrations for tlve different 
concentrations (0.15 mg/ml, 0.30 mg/ml, 0.60 mg/ml, 1.00 mg/ml and 2.00 
mg/ml) of the drug Xanthinol nicotinate at 48 hour of incubation has been 
summed up in Table 11. According to the table, percentage of aberrant 
metaphases did not increase linearly with the increased drug concentrations, 
but the effect was low (58%) at lower drug concentration (0.15 mg/ml) and 
was highest (61%) at the highest tested concentration (2.00 mg/ml). All the 
values in the range were statistically highly significant as compared to the 
negative control (4.33%) at P < 0.005. 
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Study of aberrations per cell also revealed similar results. According 
to the table, aberrations per cell were 0.83 at initial concentration (0.15 
mg/ml) of the drug, while at final drug concentration of 2.00 mg/ml. 
aberrations per cell got increased to 1.16. Statistically all the values were 
highly significant as compared to negative control values. The results of the 
positive control were also significant at P < 0.005 at 48 hour of incubation. 
The relationship between aberrant metaphase frequencies and applied 
concentrations of the drug is depicted in graphs where the increasing bar 
lengths (symbolizing increased aberrant metaphase frequencies) was 
observed with increasing drug concentrations respectively (Fig. 13). 
Regression study of aberrations per cell revealed dose-response curve 
plotted for increasing drug concentrations versus increasing aberrations per 
cell. A positive correlation was found between above two measurements 
(correlation coefficient, R = 0.42). The best fit regression line determined b\ 
least squares method along with regression line equation is given in Fig. 14. 
(b) Micronucleus frequency and Binucleated mirconucleated cell 
frequency: 
The results of the CBMN assay for Micronucleus (MN) frequencies 
and Binucleated Mirconucleated (BNMN) cell frequencies are summarized 
in Table 12 and Table 13 respectively. According to the Table 12, MN 
frequency has increased gradually in percent (4.3, 5.3, 5.9, 6.7 and 15.0) 
with the increasing drug concentrations (from 0.15 mg/ml to 0.30, 0.60, 1.00 
and 2.00 respectively). Statistical analysis, applying Student's t - test. 
revealed that the last four MN frequency values were highly significant with 
respect to control (1.6%) at P < 0.005. the MN frequency value at lowest 
82 
drug concentration of 0.15 mg/ml, was found to be insignificant at P < 0.005 
level of significance. 
The frequencies of BNMN cells showed linear increase of the values 
in percentage as 4.3, 5.3, 5.9, 6.7 to 10.0 with increasing drug 
concentrations. These values were similar to the values obtained for MN 
frequencies. Only last readings of both the parameters differ from each 
other. Considering the statistical analysis of BNMN cell frequencies, the last 
four values were highly significant at P < 0.005 as compared to control 
values. The first value was found to be insignificant at P < 0.005. 
Analysis of regression graph of micronucleus frequencies and drug 
concentrations plotted against each other revealed a dose - response curve. 
Graph shows a good positive correlation between observed MN frequencies 
and applied drug concentrations (correlation coefficient, R = 0.96). The best 
fit regression line for the relationship between the two measures and the 
equation describing it is presented in Fig. 15. 
Analysis of bar diagram of BNMN frequencies for different drug 
concentrations shows increase as depicted in gradual elevation of bar lengths 
with increased drug doses respectively (Fig. 16). 
(a) Nucleoplasmic bridge frequencies: 
Table 13 indicates the results of nucleoplasmic bridge (NPB) 
frequencies induced by Xathinol nicotinate. The table shows relative 
occurrence of nucleoplasmic bridges in 1000 binucleated cells. As given in 
the table, NPB frequencies showed consistent increase in value with 
increased drug doses, except at 0.60 mg/ml drug concentration where the 
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value (50.0%) is very high as compared to the values (33.3%) at 
concentrations higher than this. But an over all increased response was 
observed comparing lowest drug dose (0.15 mg/ml) and highest drug dose 
(2.00 mg/ml) respectively. At 0.15 mg/ml concentration, the NPB frequency 
was 8.3 % while at 2.00 mg/ml concentration the NPB frequency increased 
to 33.3 %. All the values were greatly significant at P < 0.005 as compared 
to the control (1.8%). 
The dose-dependant nucleoplasmic bridge frequencies are also shown 
in Fig. 16, where increased bar lengths (representing nucleoplasmic bridge 
frequencies) were observed with increasing drug doses (from 0.15 mg per ml 
to 0.30, 0.60, 1.00 and 2.00 respectively). 
(b) Nuclear bud frequencies: 
Table 13 presents the results of nuclear bud (NB) frequencies given 
against different concentrations of the drug Xanthinol nicotinate. The Table 
shows that, at the initial three drug concentrations, i.e., 0.15 mg/ml, 0.30 
mg/ml and 0.60 mg/ml, nuclear buds were not at all scored. Where as there 
were 7.7% and 12.5% of NB frequencies scored for the last two dmg doses 
(1.00 mg/ml and 2.00 mg/ml) respectively. Both these values were 
statistically highly significant as compared to the control values (1.5%) at P 
< 0.005. 
The NB frequencies drawn against drug doses showed the increased 
bar length pattern with increased drug concentrations respectively (Fig. 16). 
(c) Nuclear Division Index (Cell Division Kinetics) : 
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The data for nuclear/cell division kinetics of the drug Xanthinol 
nicotinate is presented in Table 14. Viable cells with one, two, three and four 
nuclei are also scored in the table. The NDI values decreased gradually with 
increasing drug concentrations. The observed range was 1.10, 1.11, 1.21. 
1.11 and 1.06 for the increased drug concentrations of 0.15 mg/ml, 0.30 
mg/ml, 0,60 mg/ml, 1.00 mg/ml and 2.00 mg/ml respectively. A slightly 
higher value (1.21) was noticed in the middle of the series at 0.60 mg/ml 
drug concentration. All the values were statistically highly significant at P < 
0.005 when compared to control which has an NDI value of 1.24. The study 
of the decline in NDI values revealed that Xanthinol nicotinate disturbed 
cell-proliferation kinetics producing a significant cell cycle delay. 
Regression analysis of the NDI showed a negative con-elation 
between the two variables, i.e. drug concentrations and NDI (coiTelation 
coefficient, R = 0.45). The best fit regression line determined by least 
squares method along with regression line equation was presented in Fig. 17. 
(d) Nuclear Division Cytotoxicity Index (NDCI): 
The data of nuclear division cytotoxicity index (NDCI) for the drug 
Xanthinol nicotinate has been given in Table 15. Mononucleated, 
binucleated, trinucleated, tetranucleated, apoptotic and necrotic cells were 
also included in the table. Analysis of the data showed that NDCI value was 
1.07 at the lowest drug concentration (0.15 mg/ml) and gets decreased to 
1.06 at highest drug concentration of 2.00 mg/ml. At drug concentrations 
0.30 mg/ml and 0.60 mg/ml the NDCI values were increased showing a 
divergent mode from rest of the data. Analysis of the whole data of NDCI 
revealed that the drug Xanthinol nicotinate did not impose significant effect 
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Fig. 13. Frequencies of aberrant metaphases plotted against different 
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Fig. 14. Dose-response curve of aberrations per cell in human 
lymphocytes in vitro treated with different concentrations of 
Xanthinol nicotinate. 
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Fig. 16. Frequencies of binucleated micronucleated cells, nucleoplasmic 
bridges and nuclear buds in human lymphocytes in vitro plotted 
against different concentrations of Xanthinol nicotinate. 
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Fig. 18. Dose-response curve of nuclear division cytotoxicity indices in 
human lymphocytes in vitro treated with different 
concentrations of Xanthinol nicotinate. 
over cell cycle kinetics and was thus not much cytotoxic. A lower cell 
cycle delay which was measured as a slight reduction in the NDCI values 
was noticed. Statistically speaking, all values were highly significant at P< 
0.005 compared with the control value (1.192). 
Study of regression graph showed a negative correlation (Correlation 
Coefficient R = 0.51) between drug concentrations and NDCI values. The 
best fit regression line together with the line equation was presented in Fig. 
18. 
4. METOPROLOL TARTRATE (METOLAR®) 
(a) Chromosomal aberrations: 
The effects of different concentrations of the drug Metoprolol tartrate 
on chromosomal aberrations in human peripheral blood lymphocytes in vitro 
have been summarized in Table 16. The drug concentrations used were from 
0.15 mg/ml to 0.30, 0.60, 1.00 and 2.00 mg/ml applied at 48 hours of 
incubation of culture. According to the table percentage of aberrant 
metaphases was found to be increased accordingly with three initial 
concentrations of the drug (0.15 mg/ml, 0.30 mg/ml, and 0.60 mg/ml) as 
46.15, 50.0 and 61.5% respectively. Cell death was noticed for the last two 
drug concentrations. Aberrations per cell have also been calculated for the 
first three drug concentrations. These values also showed an increasing 
pattern (0.69, 0.83, and 1.01 respectively) with increasing concentrations. 
Statistical analysis of data revealed that the obtained values were highly 
significant at P < 0.005, compared with the negative value. Positive control 
also showed high significance at P <0.005. 
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Graphical observations also indicated the high frequencies of aberrant 
metaphases plotted against increased drug concentrations (Fig. 19). 
Regression analysis of aberrations per cell for the drug Metoprolol 
tartrate against increased drug concentration showed a dose-response curve. 
A very strong positive correlation was found between above two 
measurements (correlation coefficient, R = 0.99). The best fit regression line 
determined by least squares method along with regression line equation is 
shown in Fig. 20. 
(b) Micronucleus frequency and Binucleated mirconucleated cell 
frequency: 
The micronucleus (MN) frequencies and binucleated mirconucleated 
(BNMN) cell frequencies results are given in Table 17 and Table 18 
respectively. According to Table 17, exposure of peripheral blood 
lymphocytes (in culture) to drug Metoprolol tartrate for 24 hours induced 
elevated numbers of MN (from 1.5% to 4.3, 5.7, 8.3 and 9.1%) at 
concentrations (mg/ml) from 0.15 to 0.30, 0.60, 1.00 and 2.00 respectively. 
Analyzed statistically, the initial MN frequency value (at lowest drug 
concentration) was insignificant, MN frequency value at next concentration 
was found to be significant, whereas the last three MN frequency values 
were highly significant with respect to control at P < 0.005. 
Table 18 shows that the frequencies of BNMN cells also increased in 
percentage from 1.5, 4.3, 5.7, 8.3 to 9.1 with increasing drug concentrations. 
This increase was similar with the increase of MN frequencies at all 
concentrations. The statistical result of BNMN cell frequencies, applying 
Student's t - test, also showed the same significance level in case of MN 
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induction. Here also the last three values were highly significant at P < 0.005 
as compared to control value at 24 hour of incubation. The first one was 
insignificant and second one was significant at P < 0.005. 
Regression graph analysis of micronucleus frequencies plotted against 
drug concentrations revealed dose - response curve. The observed MN 
frequencies were correlated strongly and positively (Correlation Coefficient 
R = 0.88) with increased drug concentrations. The best fit regression line 
together with the line equation determined is presented in Fig. 21. 
The bar diagram analysis of BNMN cell frequencies plotted against 
increasing drug concentrations also showed increased bar lengths (indicating 
BNMN fi-equencies) with increasing drug doses respectively (Fig. 22). 
(a) Nucleoplasmic bridge frequencies: 
The results of nucleoplasmic bridge (NPB) frequencies induced by the 
drug Metoprolol tartrate are summarized in Table 18. According to the table, 
the NPB frequencies did not show consistent increase with increasing drug 
doses, but an over all increase in the effect was observed when NPB 
frequency at lowest drug concentration was compared with the NPB 
frequency at highest concentration of the drug. At 0.15 mg/ml concentration, 
the NPB frequency was 13.3 % while at 2.00 mg/ml concentration the NPB 
frequency was increased to 28.6 %. Statistically the result was highly 
significant at P < 0.005 as compared with the control (with 1.8% NPB 
frequency). 
The relative increase of nucleoplasmic bridge frequencies between 
lowest and highest concentrafions is presented in Fig. 22. Here NPB 
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frequencies were plotted against different concentrations in the form of bar 
graph. Increased bar lengths (presenting elevated NPB frequencies) were 
obtained with increasing drug doses (mg/ml) (from 0.15 to 0.30, 0.60, 1.00 
and 2.00). 
(b) Nuclear bud frequencies: 
The results of nuclear bud (NB) frequencies are also depicted in Table 
18. Study of the table showed that nuclear bud frequencies increased with 
increasing drug concentrations respectively. A little drop in the value was 
noticed at 1.00 mg/ml drug concentration. The observed range, in 
percentage, was from 7.1 to 9.1, 10.3, 9.1 to 11.1 respectively. Observed 
data indicated the effect has increased with increased drug concentrations 
(0.15 mg/ml, 0.30 mg/ml, 0.60 mg/ml, 1.00 mg/ml and 2.00 mg/ml). 
Statistical analysis showed that all the values were highly significant at P 
<0.005 level, as compared with the control value. 
The increasing bar lengths, symbolizing the increased NB frequencies, 
are noticed again with increasing drug concentrations as shown in graph 
(Fig. 22). 
(c) Nuclear Division Index (Cell Division Kinetics): 
The study of nuclear division index (NDI) results for the drug 
Metoprolol tartrate are summarized in Table 19 which also contains 
mononucleated, binucleated, trinucleated and tetrsnucleated cells. The 
extent and progression of nuclear division could be assessed by analyzing 
the data. According to the table a step wise increase and decrease in the 
NDI values has been noticed with increasing drug concentrations. These 
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values were 1.10, 1.01, 1.04, 1.01 and 1.05 obtained for O* 15 mg/ml, 0.30 
mg/ml, 0.60 mg/ml, 1.00 mg/ml and 2.00 mg/ml drug concentrations 
respectively. The relative dose-response studies revealed a decrease in the 
NDI value from the lowest drug dose to the highest drug dose. At initial 
lowest concentration (0.15 mg/ml), the NDI value was 1.10, which 
decreased to 1.05 at the highest final drug concentration (2.00 mg/ml) 
demonstrating a cell cycle delay. All values were highly significant 
statistically when compared to the control value (1.24) at P < 0.005 level of 
significance. 
Regression analysis showed a weak negative correlation between drug 
concentrations and NDI (correlation coefficient, R = 0.19). The best fit 
regression line determined by least squares method along with regression 
line equation is presented in Fig. 23. 
(d) Nuclear Division Cytotoxicity Index (NDCI): 
The data of nuclear division cytotoxicity index (NDCI) for the drug 
Metoprolol tartrate is summed up in Table 20. Both, viable (mononucleated, 
binucleated, trinucleated, tetranucleated) and non - viable (apoptotic and 
necrotic) cell populations were included in the table. To study this 
parameter, a uniformly consistent result was not obtained in a decreasing 
pattern with increasing concentrations of the drug. The relatively decreasing 
effect was noticed when NDCI values were at lowest (0.15 mg/ml) and 
highest (2.00 mg/ml) drug doses. These values were 1.08 and 1.06 
respectively at 24 hour of culture incubation. The relative decline in the 
values suggested a cell cycle delay along with cellular cytotoxicity of the 
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Fig. 22. Frequencies of binucleated micronucleated cells, nucleoplasmic 
bridges and nuclear buds in human lymphocytes in vitro plotted 
against different concentrations of Metoprolol tartrate. 
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concentrations of Metoprolol tartrate. 
drug. Statistical analysis of the data, applying % 2 test, showed that all 
values were highly significant at P< 0.005 compared with the control value 
(1.192). 
Best fit regression line graph plotted for increased concentrations of 
the drug against obtained respective NDCI values showed a very weak 
negative correlation between the two measurements (correlation coefficient, 
R - 0.05). The regression line and the equation representing it are both 
shown in Fig. 24. 
Comparative analysis of the Pentoxifylline, Isoxsuprine hydrochloride, 
Xanthinol nicotinate and Metoprolol tartrate 
The above four tested cardiovascular drugs were also analyzed 
together to assess their relative c}4ogenotoxic potential. The data is 
summarized in Tables 21, 22 and 23respectively. Average mean values (± 
Standard error of mean, SEM) of the measurements (percent aberrant 
metaphases, aberrations per cell, micronucleus frequencies, binucleated 
mirconucleated cell frequencies, nucleoplasmic bridge frequencies, nuclear 
bud frequencies, nuclear/cell division kinetics and nuclear division 
cytotoxicity index) were studied for each drug, all the four drugs being 
grouped under one table. 
Table 21 contains comparative analysis of average mean (± SEM) 
frequencies of aberrant metaphases per 100 normal metaphases and 
aberrations per cell in four test drugs. According to this table, percent 
aberrant metaphases were highest in drug Isoxsuprine hydrochloride 
(60.79%) followed by Pentoxifylline (53.96%), Metoprolol tartrate (52.55%) 
and Xanthinol nicotinate (49.40%). A differing result was obtained for 
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aberrations per cell study where the effect was highest in drug Xanthinol 
nicotinate (1.16) followed by Pentoxifylline (0.98), Metoprolol tartrate 
(0.84) and Isoxsuprine hydrochloride (0.78). These results are also shown 
graphically in Fig. 25. 
Studies of the structural aberrations induced by these drugs show 
mainly chromatid-type of aberrations consisting of terminal deletions, breaks 
etc in one arm of the chromosome. Some chromosome-type aberrations were 
also seen (rings, dicentric chromosomes) (Fig. 29 - Fig. 50). 
Comparative analysis of average means (± SEM) of micronucleus 
frequency (%), binucleated mirconucleated cell frequencies (%), 
nucleoplasmic bridge frequencies (%) and nuclear bud frequencies (%) of 
four test drugs is given in Table 22 and Fig. 26. Table showed contrasting 
outcomes considering all these parameters. Data for micronucleus frequency 
revealed highest percentage in drug Isoxsuprine hydrochloride (8.48%). The 
trail being followed by Xanthinol nicotinate (7.44%), Pentoxifylline (7.04%) 
and Metoprolol tartrate (5.78%)). 
Relative study results of binucleated mirconucleated cell frequencies 
indicated highest frequency in drug Isoxsuprine hydrochloride (7.68%) 
followed by Xanthinol nicotinate (6.44%)), Pentoxifylline (6.04%o) and 
Metoprolol tartrate (5.78%)). These results were similar to the results of the 
MN frequency parameter. 
Results of the average of mean nucleoplasmic bridge frequencies 
demonstrated greatest effect by the drug Xanthinol nicotinate (27.84%)), then 
Isoxsuprine hydrochloride (7.6820.56%), Pentoxifylline (17.26%) and lastly 
Metoprolol tartrate (13.76%o). 
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Analysis of data for nuclear bud frequencies indicated greatest 
frequency in drug Xanthinol nicotinate (10.10%) followed by Metoprolol 
tartrate (9.34%), Isoxsuprine hydrochloride (7.40%) and Pentoxifylline 
(5.04%). 
Data for comparative analysis of average mean nuclear division index 
(NDI) and average mean nuclear division cytotoxicity index (NDCI) values 
of four drugs is presented in Table 23. According to this table all the four 
drugs showed nearly the same NDI and NDCI values, with slight 
differences, indictting similar response to cell cycle delay and cellular 
cytotoxicity. For NDI the drugs were arranged accordingly for the response 
as Isoxsuprine hydrochloride (1.20), Xanthinol nicotinate (1.11), 
Pentoxifylline (1.10) and Metoprolol tartrate (1.04). Drugs with comparative 
NDCI values were arranged as Isoxsuprine hydrochloride (1.17), Xanthinol 
nicotinate (1.10), Pentoxifylline (1.08) and Metoprolol tartrate (1.05). All 
the four cardiovascular drugs demonstrated nearly same cell division 
kinetics results (Fig. 27 and Fig. 28). 
Fig. 51 - Fig. 66 represent results of the CBMN assay, obtained in the 
form of affected cell/nuclear shapes like binucleated, trinucleated and 
tetranucleated cells, micronuclei, cytoplasmic bridges, nuclear buds, 
apoptotic and necrotic cells etc. 
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Fig. 25. Average of mean frequencies of aberrant metaphases and 
aberrations/cell in four cardiovascular drugs plotted against 
different concentrations of all 4 drugs. 
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Fig. 26. Average of mean frequencies of binucleated micronucleated cells, 
nucleoplasmic bridges and nuclear buds in 4 cardiovascular drugs 
plotted against different concentrations of all drugs. 
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Fig. 27. Dose-response curve of average mean nuclear division indices 
in human lymphocytes in vitro in four tested drugs treated 
with different drug concentrations. 
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Fig. 28. Dose-response curve of mean nuclear division cytotoxicity 
indices in human lymphocytes in vitro in four tested drugs 
treated with different drug concentrations. 
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Present study has been done to evaluate and assess the in vitro 
cytogenotoxic effects of some clinically recommended cardiovascular drugs, 
mainly antihypertensive vasodilators. Herein different parameters used 
during the study including the selection of drugs of study, selection of test 
system, advantages and disadvantages of the chosen test system, the 
parameters assayed during the study and the cytogenotoxic responses and 
effects of the selected cardiovascular drugs evaluated on these parameters 
have been discussed. 
SELECTION OF TEST DRUGS 
A cardiovascular problem is considered as the second most dreaded 
challenge the world faces today. About a quarter of the world's population 
has been estimated to have hypertension at the turn of the millennium 
(Kearney, et al, 2005; Vaidya, et al., 2007). The main factor leading to this 
widespread and chronic problem is hypertension (Staessen, et al., 2001). 
Hypertension, being chronic, requires long-term drug therapy and thus 
interaction of antihypertensive drugs and their metabolites is continual with 
the human system. The continuing drug interaction may cause various types 
of side effects including those that affect human hereditary material, i.e.. 
DNA. Thus, in order to evaluate the possible cytogenotoxic response that 
the drugs may cause, four antihypertensive vasodilator drugs. Pentoxifylline 
(Trental"), Isoxsuprine hydrochloride (Duvadilan^), Xanthinol nicotinate 
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(Complamina*^) and Metoprolol tartrate (Metolar*), have been selected for 
the study. 
GENERAL CONSIDERATIONS 
The preservation of integrity of DNA as a genetic blue print is of 
prime importance for any living organism including humans. Damage 
inflicted upon the genetic material may lead to harmful effects in the cell or 
in the organism as a whole. Thus, human health safeguard is the main aim to 
study and evaluate the cytogenotoxic potentialities of cardiovascular drugs 
which are mostly used for long-term therapy. In order to assess adequately 
any expression of genotoxicity, the direct use of human system, exposed to 
these drugs, or the involvement of a system that has the same sensitivity of 
response as the human genome is preferred. This can be achieved by 
utilizing human peripheral blood lymphocyte culture system which provides 
a large number of dividing cells potentially yielding good enough amount of 
mitotic metaphase plates used for chromosome analysis. Peripheral blood 
lymphocytes represent a good indicator of exposure to genotoxic agents, 
carrying information on both doses and genotoxic effects (Morimoto, et al., 
1993; van Asten, et al, 1998; Anderson, 1999). Circulating throughout the 
body, the peripheral blood lymphocytes provide an estimate of average 
whole body exposure (Tucker and Preston, 1996). The lymphocytes also 
contain some metabolizing enzyme systems that can be able, to some extent. 
to activate certain promutagens into a mutagenically active state (Buckton 
and Evans, 1982; Preston, 1999). 
EVALUATION OF TEST SYSTEMS 
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The first stage in the evaluation of a chemical is to investigate the 
ability of the chemical to interact with DNA and produce a detectable 
change in the genetic material. Bacterial, yeast, plant, Drosophila, and in 
vitro mammalian cell assays are designed for this purpose (IPCS, WHO. 
1985). 
A large number of genotoxicity tests are presently available for use in 
hazard evaluation. These tests detect the two main categories of mutations, 
gene mutation and chromosomal aberration, as well as indications of DNA 
damage. Direct or indirect effects of DNA damage can be observed as 
cytogenetic end points, in the form of changes in chromosome structure, 
changes in chromosome numbers, micronuclei and sister chromatid 
exchanges (Obe, et al., 1982). Tests to assess these endpoints can be carried 
out both in vitro and in vivo, with in vivo tests being conducted in germ cells. 
as well as in somatic cells. In order to assess adequately any expression of 
genotoxicity, a simplified systematic approach to the selection of these tests 
is required. Therefore, there must be an ordered approach using a limited 
number of well-defined tests that complement each other in terms of 
endpoints, and that permits a systematic assessment of genotoxicity 
(Environmental Health Directorate, Canada, 1993). 
It is ideal to study the effects of chemicals directly on persons exposed 
to these chemicals or drugs (Gebhart, 1982, 1984). But due to ethical reasons 
the //; vivo study is possible only in specific cases when individuals have 
been exposed to the agents either as a chemotherapeutic necessity or 
occupational inevitability or accidental reasons. 
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Besides, the in vivo testing systems have their own limitations. 
Standard in vivo tests are unable to provide additional useful information for 
some compounds. This includes compounds for which data from studies on 
toxicokinetics or pharmacokinetics indicate that they are not systemically 
absorbed and therefore are not available for the target tissues in standard in 
vivo genotoxicity tests. Examples of such compounds are some radioimaging 
agents, aluminum based antacids, and some dermally applied 
pharmaceuticals. In cases where a modification of the route of 
administration does not provide sufficient target tissue exposure, it may be 
appropriate to base the evaluation only on in vitro testing (Hutchinson. 
2004). Other short coming of in vivo genotoxicity is that in case of exposed 
model the cytogenetic abnormalities studied represent the most drastic and 
obvious expressions of genetic damage, but the frequent and subtle genetic 
changes, like mutations, can not be detected. 
To overcome the shortcomings of the in vivo, testing systems, in vitro 
assays are preferred. In vitro cytogenetic tests are designed to demonstrate 
the induction of chromosome damage (aberrations), visible under the light 
microscope, in cuhured cells. A physical or chemical agent is classified as a 
clastogen if it produces an increase in the number of breaks in chromosomes 
over that found in control samples. Cytogenetic tests therefore assess gross 
damage to the DNA involving at least one double-strand break. The 
experimental approach can be use and the effect of drugs/chemicals can be 
evaluated at a range of concentrations (including subtoxic and toxic levels) 
on lymphoc}1:e cultures of healthy donors. Evaluation of the response of 
cells at different time exposures to the drugs and the fate of lesion after 
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consecutive cell division along with the drug effect during G] as well as S-
phase of the cell cycle can also be evaluated in the in vitro cytogenetic assay. 
However, in vitro cytogenetic test has its own shortcomings because 
of the absence of metabolizing system of drugs and chemicals. Lymphocytes 
can only metabolize some compounds. Some other compounds have also 
been metabolized due to the presence of erythrocytes which aid the 
metabolic process (Wilmer, et al., 1984) 
EVALUATION OF THE PARAMETERS ASSAYED 
To test whether pharmaceuticals are genotoxic or not, normally, two 
short-term, high precision, in vitro tests are considered to be sufficient. 
These include the chromosome aberration assay and the cytokinesis-blocked 
micronucleus (CBMN) assay, both utilizing the peripheral human 
lymphocytes as the base. 
The chromosome aberration test using cultured mammalian cells is 
one of the most sensitive methods to predict environmental mutagens and/or 
carcinogens, and is a complementary test to the Salmonella/microsome assay 
(Ames test) (Ishidate, et al., 1998). The parameter usually assessed via this 
assay is chromosomal aberrations. 
The study of DNA damage at the chromosome level is an essential 
part of genetic toxicology because chromosomal mutation is an important 
event in carcinogenesis. The micronucleus assays have emerged as one of 
the preferred methods for assessing chromosome damage because they 
enable both chromosome loss and chromosome breakage to be measured 
reliably. Because micronuclei can only be expressed in cells that complete 
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nuclear division, a special method was developed that identifies such cells 
by their binucleate appearance when blocked from performing cytokinesis 
by cytochalasin-B (Cyt-B), a microfilament-assembly inhibitor. This 
recognition prevents the confounding effects caused by differences in cell 
division kinetics (Kirsch-Volders, et al., 2001; Fenech, 2002). Thus, the 
cytokinesis-blocked micronucleus (CBMN) assay, more recently known as 
the CBMN "cytome" or CBMN-Cyt assay (Fenech, 2007), is a multi-
endpoint assay that allows better precision because the data obtained are not 
confounded by altered cell division kinetics caused by cytotoxicity of agents 
tested or sub-optimal cell culture conditions. In its current basic form the 
CBMN assay provides, using simple morphological criteria, the different 
measures of genotoxicity and cytotoxicity. These measures involve 
chromosome breakage, chromosome loss, chromosome rearrangement 
(nucleoplasmic bridges), cell division inhibition, necrosis and apoptosis 
(Fenech, 2000). 
Chromosomal alterations/aberrations: 
Chromosomal aberration assessment serves as a good indicator of the 
clastogenic effects of agents (Buckton and Evans, 1982; Hsu, 1982). 
Aberrations are divided into chromatid-type and chromosome-type, the first 
involving only one chromatid, the latter, both chromatids at identical sites. 
The chromatid-type aberrations are caused in the So or G2 stage of cell 
cycle, and include chromatid gaps, breaks and deletions, while chromosome-
type aberrations are found in Gi or early S-phase of the cell cycle and 
include isochromatid gaps, ring chromosomes, acentric fragments and 
interstitial deletions (Hsu, 1982). 
120 
Breaks can be distinguished from exchange configurations by their 
physical appearance at metaphase rather than by their mode of formation. 
Breaks are true discontinuities with clearly dislocated fragments and also 
include fragments without obvious origin. They should not be confused 
with achromatic lesions (gaps), which do not represent true discontinuity in 
the DNA. It is generally assumed that gaps are sites of despiralization in the 
metaphase chromosome that render the DNA non-visible under light 
microscopy (IPCS. WHO, 1985). It has been proposed that an achromatic 
lesion may actually be a single-strand break in the DNA double helix as a 
result of incomplete excision repair and, thus, may represent a point of 
possible instability (Bender, et al., 1974). Therefore, gaps are always noted 
but reported separately from true chromosomal aberrations. 
Micronuclei (MNi): 
MNi are expressed in dividing cells that either contain chromosome 
breaks lacking centromeres (acentric fragments) and/or whole chromosomes 
that are unable to travel to the spindle poles during mitosis. At telophase, a 
nuclear envelope forms around the lagging chromosomes and fragments, 
which then uncoil and gradually assume the morphology of an interphase 
nucleus with the exception that they are smaller than the main nuclei in the 
cell, hence are known as "micronucleus". MNi, therefore, provide a 
convenient and reliable index of both chromosome breakage and 
chromosome loss. Enumeration of micronuclei in mitogen-stimulated 
lymphocytes provides a simpler and statistically more precise method for 
quantification of chromosomal damage (Fenech and Morley, 1985; Kirsch-
Volders, er a/., 1997). 
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Binucleated micronucleated cells: 
In the CBMN assay, cells that have completed one nuclear division 
are blocked from performing cytokinesis using cytochalasin-B and are 
consequently readily identified by their binucleated appearance. MNi are 
scored in binucleated cells only, which enables reliable comparisons of 
chromosome damage between cell populations that may differ in their cell 
division kinetics. 
Nucleoplasmic bridges: 
These are considered as dicentric chromosomes in which the two 
centromeres were pulled to opposite poles of the cell and the DNA in the 
resulting bridge covered by nuclear membrane. They provide a measure of 
asymmetrical chromosome rearrangement (owing to misrepair of DNA 
strand breaks or possibly telomere end-joining) (Thomas, et al., 2003). Thus 
are scored together with the micronucleus count. 
Nuclear buds: 
Nuclear buds are the out growths from main nucleus which get 
attached to nucleus through nucleoplasmic connections. Nuclear buds are 
supposed to result due to the induction of gene amplification that may lead 
to extrusion of amplified genes during S-phase. These buds are eventually 
detached from the nucleus to form a micronucleus (Shimizu, et a!., 1998; 
Fenech, 2002). The frequency of nuclei with nuclear bud formation is scored 
if gene amplification is suspected. 
Cell/nuclear division kinetics: 
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Cell/nuclear division kinetics is assessed by scoring cells with one. 
two, three and four nuclei in CBMN assay. The index used for the 
calculation of division status is known as nuclear division index (NDI).The 
NDI provides a measure of the proliferative status of the viable cell fraction. 
It is therefore an indicator of cytostatic effects and, in the case of 
lymphocytes, it is also a measure of mitogenic response, which is useful as a 
biomarker of immune function (Chandra, 2002). The lowest NDI value 
possible is 1.0, which occurs if all of the viable cells have failed to divide 
during the cytokinesis-block period and are therefore all mononucleated. If 
all viable cells completed one nuclear division and are therefore all 
binucleated, the NDI value is 2.0 (Fenech, 2007). The calculation of the NDI 
when compared with the control, used during the study, reveals the 
significant cell cycle delay or progression detectable after exposing culture 
cells to varying concentrations of the drug. 
Nuclear division cytotoxicity index: 
The more accurate assessment of nuclear division status is obtained by 
including necrotic and apoptotic cells in the total number of cells scored. It 
is because at higher toxic doses of chemicals tested a very large proportion 
of cells became non-viable. In that case both binucleate cell ratio and the 
NDI became overestimated if necrotic and apoptotic cells were not included 
in scoring cells. Thus, at higher toxicity levels the precise estimate of 
nuclear division status and cell division kinetics is obtained using the nuclear 
division cytotoxicity index (NDCI) which takes into account both viable as 
well as necrotic and apoptotic cell fractions (Fenech, 2000). Any change in 
NDCI values following drug exposure compared to concurrent control, 
provides information on cell cycle progression and cellular cytotoxicity. 
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CYTOGENETIC EFFECTS OF THE VASODILATOR 
ANTIHYPERTENSIVE DRUGS IN VITRO 
Antihypertensive vasodilators are drugs that are recommended for the 
treatment of peripheral vascular diseases, high blood pressure problems, 
cardiac problems like stroke and other cerebral vascular diseases etc. 
depending on the function and class of that particular antihypertensive drug. 
These cardiac problems are, nowadays, commonly encountered. Thus, 
in the present investigation, keeping in mind the v^idespread, long-term and 
continual use of vasodilator antihypertensives, four such drugs are tested for 
their genotoxic potential in human peripheral lymphocytes in vitro. No such 
type of study has been done previously in three of these drugs, namely, 
Isoxsuprine hydrochloride (Duvadilan"), Xanthinol nicotinate 
(Complamina*^) and Metoprolol tartrate (Metolar*^). Whereas, some stud\ 
has earlier been done (Bozsakyova, et al, 2001) over the genotoxicity of the 
third drug Pentoxifylline (Trental*). 
In the present study, we have estimated the rate of chromosomal 
instability in the cultured human lymphocytes treated with four above 
cardiovascular drugs. Concerning the results obtained in our present in vitro 
studies, all the four drugs, at applied concentrations, are found to have 
statistically significant enhancement of variables of chromosomal aberration 
assay and cytokinesis-block micronucleus assay. Most of these effects have 
been reported for the first time in our study. 
Considering the evaluation of these drugs through chromosomal 
aberration studies, in peripheral blood lymphocytes in vitro, it is noticed that 
the drugs significantly increase the drug induced frequencies of aberrant 
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metaphases as compared with their concurrent control. A much higher then 
normally obtained percentage of abnormal metaphases have been reported in 
present study in case of all the four test drugs. 
Studied individually, out of the four drugs, the highest response was 
given by drug Isoxsuprine hydrochloride (Duvadilan®). This drug induced 
75% aberrant metaphases at concentration of 1.00 mg/ml. Rest three drugs 
also induce significantly high percentage of abnormal metaphases at their 
respective concentrations demonstrating a positive correlation with 
increasing drug doses. 
In case of the drug Metoprolol tartrate (Metolar®), the increasingly 
toxic effect of higher drug concentration resulted in cell death for last two 
drug doses. 
Considering gross structural t>pe of chromosomal abnormalities, 
chromatid- type of aberrations was more common in all the test drugs 
indicating a clastogenic response of the drugs towards human lymphoc}tes 
in vitro. The prevalence of- type of aberrations suggest S-dependency of the 
drugs. It is well known, that the type of aberrations induced by genotoxic 
agents are cell cycle dependent. Most of the chemically induced aberrations 
are formed only during the DNA synthesis phase (probably due to 
misreplication). Such chemical agents induce mainly chromatid-type 
aberrations and are also very efficient in inducing sister chromatid 
exchanges (Natarajan, 1993). 
Structural Chromosomal aberrations are thought to be induced due to 
the double-stranded breaks (Obe, et a/., 1982), although single-stranded 
breaks may also play a quantitatively minor role. Dicentric chromosomes 
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and acentric fragments have been originated as a result of asymmetrical 
recombinations relative to the centromere. These acentrics may give rise to 
the formation of micronuclei. Aberrations in chromosome number arise from 
disturbances of the mitotic cell division process (Baan, 1987). 
Assessment of cytogenetic response of the drugs under study via 
variables of CBMN assay suggested their statistically significant positive 
involvement in the induction of chromosome loss and rearrangement. 
Drug induced enhanced micronucleus frequencies were found in vitro 
for all he four drugs, the highest result being obtained in pentoxifylline and 
Xanthinol nicotinate. Both these drugs induce 15% micronucleus 
frequencies. Such a high percent induction suggested the involvement of 
aneuploidy (specifically chromosome loss) phenomena in the origin of drug-
induced MN in vitro. The significantly increased frequencies of MN in vitro 
could be related to the lack of metabolic clearance of these drugs b> 
lymphocytes in culture. 
Other variables of the assay like binucleated mirconucleated cell too 
get positively affected by the increasing drug concentration. Increasingly 
high frequencies of these cell types indicate cytogenetic responsiveness of 
the drugs. 
Studies of chromosomal rearrangements via nuclear bridge formation 
in binucleated cells in drug treated cultures at 24 hour of incubation show a 
significantly increasing dose-dependent response. All the four vasodilator 
antihypertensive drugs induce chromosomal rearrangements in cultured 
human lymphocytes. 
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Concerning the cytogenetic effect of the drugs in terms of the 
appearance of nuclear buds, the increasingly positive dose-dependent 
response show involvement of gene amplification induced by test drugs. The 
highest responsive drug being Xanthinol nicotinate. However, this drug 
shows no bud frequency at all at some initial concentration. Thus higher 
dose of the drug resulted in gene amplification. 
More cytogenotoxic effects of the drugs under study were assessed by 
studying the cell/nuclear kinetics of the test drugs in human lymphocytes at 
vaying concentrations of the drug. A significant data suggested that a ver> 
clear cell cycle delay and cellular cytotoxicity was caused by the test drugs. 
Remarkably reduced NDI and NDCI values were achieved at increasing 
concentrations of the drug, the exposure time being kept constant. The 
highest cell cycle delay was observed by the drug Pentoxifylline, ver\' 
closely followed by Isoxsuprine HCl. Other drugs also follow the response. 
NDCI values also pointed out notable cell death response in the form of an 
increment in apoptotic and necrotic cells in human cultured lymphocytes in 
vitro. These results suggested a positive in vitro cytotoxic response of the 
drugs under concern. 
In the present study, very high frequencies of some significantly 
positive responses including chromosomal aberration frequencies and 
greater number of nuclear bridges and nuclear buds which have been 
obtained as a results of the treatment of human peripheral blood 
lymphocytes with increasing concentrations of test drugs, may be justified 
due to the use of very high concentrations, in mg/ml, of the drugs. 
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The contrasting results, at different concentrations of treatment, for 
one or the other parameter analyzed, may appeared due to some handling 
mistakes and cross reactions. The overall estimates, otherwise, were 
consistent. 
Concerning the comparative analysis of the data of all the four 
cardiovascular treatment drugs, takmg each assayed parameter separately, it 
was noticed that no single drug was highly differentially responsive to any 
parameter. Comparison of average mean values (± SEM) of data for each 
variable gave an overall average assessment of obtained response for each 
drug. In case of mean percent aberration metaphases and mean aberrations 
per cell reports all the four drugs showed high response. Drug Isoxsuprine 
HCI gave a slightly more reactive response by inducing 75% aberrations, 
then the rest three. While aberration per cell data was more for the drug 
Xanthinol nicotinate. In case of induction of micronuclei and occurrence of 
BNMN cells again the drug Isoxsuprine HCI showed more percentage. 
Taking nucleoplasmic bridges and nuclear buds into consideration, the 
highest response was given by drug Xanthinol nicotinate. Likewise for NDI 
and NDCI measures were more reduced for the drug Metoprolol tartrate, 
indicating the highest response of this drug in cell cycle dalay and cellular 
cytotoxicity. Drug Pentoxifylline gave close rest to all these values. This 
suggested that all the four drugs show the positive cytogenetic effects over 
human lymphocytes in culture. 
When the observed genotoxic potentialities of the test drugs were 
analyzed in comparison with the studies done for other antihypertensive 
vasodilator drugs, our data was in line with them. Although much studies 
have not been done for this class of drugs, but the available data show 
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similarities with our findings. Studying the genotoxicity of diuretic 
antihypertensive drug Hydrochlorothiazide, a clear chromosome dalay was 
found (Andrianopoulos, et al., 2006). According to an extensive survey done 
over marketed antihypertensive drugs, 32 drugs were found to be positive in 
at least one genotoxicity assay (Brambilla and Martelli, 2006). Sodium 
nitroprusside, used for the ischaemic patients undergoing nitrate therpy, 
showed cytotoxicity and cell cycle delays when studied in vitro (Andreassi, 
et al., 2001). Telez, et al. (2001) found highly induced MN frequencies 
containing whole chromosomes for another antihypertensive drug 
nimodipine in v/fro.Telez, et al. (2000) also found a significantly high 
frequency of MN in the lymphocytes of patients treated with a P-blocker 
antihypertensive drug Atenolol thus showing positive aneugenic responses 
in CBMN assay with human lymphocytes. Studies show that 
antihypertensive drugs Hydralazine and Dihydralazine can induce 
micronuclei in vitro, the effect depending on time of exposure and 
concentration of the drug (Chlopkiewicz, 1996). Drug Pentoxifylline was 
also tested positive to induce chromatid type aberrations in vitro 
(Slamenova, et al., 1995). Methyldopa, a widely used antihypertensive drug, 
was found to induce significant increase in the SCE frequency in human 
lymphocytes in culture (Cesar and Catarina, 1991). Also induction of 
mutation and chromosomal aberration was observed in experimental models 
following exposure to nitrogen oxides, nitrate and nitrite (Isomura, et al. 
1984; Luca, et al, 1985, 1987; Nayak, et al, 1989) and an increase of MN 
formation by nitric oxide was observed in mammalian cells using Sodium 
nitroprusside as a drug donor of NO (Lin, et al., 1998). Thus, our data is in 
good agreement with these previous reports, the cytogenetic responses of the 
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three drugs, Isoxsuprine hydrochloride (Duvadilan®), Xanthinol nicotinate 
(Complamina*) and Metoprolol tartrate (Metolar*) being reported for the 
first time. 
Summing up, the four test drugs indicate significantly positive results 
for their cytogenotoxic potentials (clastogenic and aneugenic effects) in 
cultured peripheral blood lymphocytes in vitro, employing various 
parameters of chromosomal assay and CBMN assay techniques. Their 
chronic use may impose negative side effects on the health of the patient. 
However, in vitro analysis alone is insufficient to identify these hazardous 
effects and thus, in vivo analysis also has to be carried out (Vlastos, et ai. 
1998) to observe and evaluate the chronic exposure of the drug among the 
patients. 
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Metapfiase j>Cates sflowing cfiromosomaC 
a6errations due to tfie effects of tfie test 
drugs 
^ • ^ 
Fig. 29. A spread with fragments and breaks. Fig. 30. Dicentric chromosomes, triradii, 
and terminal deletion. 
Fig. 31. Endoredupiication, extreme 
chromatid separation. 
Fig. 32. Terminal deletion. 
%:f-
Fig. 33. Chromatid end joining of two 
different chromosomes. 
F 
* 
•ig. 34. Hypodyploidy of chromosomes 
* * • . * » 
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Fig. 35. Different chromosome shapes, 
terminal deletion. 
Fig. 36. Chromatid sticking and condensation 
Fig. 37. Terminal deletion, acentric fragment, 
and chromatid separation. 
Fig. 38. Multiple and random chromosome 
anomalies. 
Fig 39. Complete p- arm deletion. 
/ i 
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Fig. 40. Terminal deletions and chromatid 
end sticking. 
Fig. 41. Minutes and chromatid separation. Fig. 42. Chromatid gaps and chromatid 
separation. 
Fig. 43. Break at q -arm, and chromatid end 
sticking. 
Fig. 44. Chromosome condensation and 
chromatid exchange. 
Fig. 45. Chromosome rings. Fig. 46. Dicentric chromosomes. 
Fig. 47. Chromatid separation. 
Fig. 48. Hypoploidy and, arm sticking and 
terminal deletion. 
Fig. 49. q - Arm terminal deletion. 
# * ^ 
Fig. 50. Extreme chromosome condensation. 
TCates sflowing nucCear cftanges cCue to tfie 
effects oftHe test drugs 
Fig. 51. Cell population with budded, binucleated, 
necrotic and apoptotic cells along with some 
normal cells. 
Fig. 52. Normal, necrotic and budded cells. 
Fig. 53. A binucleated cell with a micronucleus. Fig. 54. A binucleated cell with a micronucleus and < 
nucleoplasmic bridge connecting both nuclei. 
Fig. 55. A binucleated cell with a micronucleus 
overlapping one nucleus. 
Fig. 56. A binucleated cell with a nucleoplasmic 
bridge connecting both nuclei. 
Fig. 57. A binucleated cell with two 
budded nuclei. Fig. 58. A trinucleated cell with two 
budded nuclei. 
Fig. 59. A binudeated cell with a 
nucleoplasmic bridge connecting both nuclei. 
Fig. 60. A binudeated, an apoptotic and 
a necrotic cell. 
Fig. 61. A mononucleate cell undergoing necrosis. Fig. 62. One necrotic and one apoptotic cell. 
I 
I 
f >i 
Fig. 63. A mononucleated cell with an 
extruding nucleus. 
Fig. 64. Plate showing a tetranucleated 
cell with one extruding nuclei. 
Fig. 65. Atrinucleated cell. Fig. 66. A tetranucleated and mononucleate 
cell. 
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